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The ability to culture pathogenic organisms enables researchers to understand the 
biology of the organism which aids in the development of vaccines and drugs. Hence the 
establishment of the protocol for the in vitro cultivation of the erythrocytic stages of 
Plasmodium falciparum revolutionized research into this important cause of human 
malaria. However, it is not possible to cultivate Plasmodium vivax, the most widely 
distributed and difficult to treat malaria parasite, due to its strict preference for 
reticulocytes. Plasmodium cynomolgi, a macaque infecting species phylogenetically close 
to P. vivax has been routinely used in animal models to study the dormant liver-stage forms 
of P. vivax. Cultivation of P. cynomolgi erythrocytic stage was reported in the early 1980s, 
has not been pursued further. In this study, we have revitalized the continuous culture of P. 
cynomolgi and systematically defined the optimal conditions for the tractable in vitro 
culture of this important P. vivax model. Importantly we have discovered that the successful 
in vitro culture of P. cynomolgi is strain dependent, with only one (Berok strain) of the 
three strains tested, is amenable to long term culture. Morphological and phenotypic 
characterisation of our P. cynomolgi (Berok strain) cultured parasites clearly show 
similarities with P. vivax. In addition to validating the potential of this culture system for 
high throughput drug screening in erythrocytic stages, a homogenous line was isolated from 
a single infected cell; paving the way for clean whole genome sequences.  
Understanding of hypnozoite biology of P. vivax remains elusive due to the lack of 
sustainable in vitro models for long term cultures of hepatocytes to capture the full liver 
stage cycle including the transition to blood stage parasites. To define the antimalarial drug 
effects in the full life cycle of P. vivax, we also developed a liver stage model using P. 
cynomolgi infected 3-dimensional (3D) hepatic spheroids which proved to be a predictive 
radical cure model which corresponds with outcomes using in vivo monkey models. The 
phosphatidylinositol-4-OH kinase (PI4K) inhibitor- KDU691 was used in this study as the 
exploratory tool compound to demonstrate the robustness of the 3D hepatic spheroid model 
in predicting in vivo outcomes.  KDU691 was chosen as it was previously proven to be 
active in the causal prophylaxis model and delayed treatment model carried out in the 
conventional 2D monolayer based assays but failed in the in vivo radical cure model using 
rhesus monkeys.  
 v 
It is hoped that the in vitro tools developed using P. cynomolgi, will accelerate P. 
vivax vaccine and drug discovery efforts through better understanding of the mechanisms 
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1.1 Malaria    
Malaria, a vector borne disease recorded for over 4000 years, still remains among 
the most devastating infectious diseases of the 21st century. Approximately 3.2 billion 
people, around half of the world’s population, are risk of contracting malaria. It affects 91 
countries globally and accounts for around 445,000 deaths yearly with extensive morbidity 
mainly in the tropical and sub-tropical countries (Figure 1.1). In 2016, there was around 
216 million cases of malaria, an increase of 5 million cases from 2015 [1]. The majority of 
malaria cases occur in sub-Saharan Africa and Asia. Children and pregnant women are 
particularly vulnerable to severe and fatal malaria. Certainly, in countries where malaria is 
endemic, severe malaria is closely linked to the poor and disadvantaged who have limited 
access to healthcare.  
 
Figure 1.1 Map of malaria endemic areas (Phillips et al.., 2017). Plasmodium falciparum 
is mainly found in the tropical regions as its gametocytes require a temperature of more 
than 21oC to mate and produce infective sporozoites in the mosquito vector. Plasmodium 
vivax is prevalent globally even in subtropical regions where the parasites are able to 
develop to infective sporozoites in the mosquito vector at temperatures as low as 16oC. 
Due to the high social and economic burden of malaria worldwide, The Roll Back 
Malaria (RBM) Partnership was launched in 1998 by WHO, United Nations Development 




coordinated global effort to eliminate the disease. The more than 500 partnerships formed 
between governments, non-governmental organizations, academic institutions, private 
companies and international organizations worldwide have facilitated malaria-control 
efforts in both global and national levels. The coordination by the RBM Partnership has 
prevented duplication and fragmentation of efforts between partners hence ensuring 
optimal use of resources. The objectives in the recent RBM Strategic Plan 2018-2020 are 
well aligned with the WHO Global Technical Strategy for Malaria 2016-2030 (GTS) where 
the goal by 2020 is to reduce global malaria incidence and mortality as compared to 2015 
by at least 40%, to eliminate malaria in at least 10 more countries as compared to 2015 and 
to prevent the re-emergence of malaria in countries declared malaria free in 2015 [2].  
US$ 2.7 billion was invested in 2016 in malaria control and elimination globally. 
Of which the majority of the investment was in sub-Saharan Africa, followed by South-
east Asia [1]. The majority of the efforts in controlling malaria are in  vector control/bite 
prevention followed by diagnostic testing and treatment [1]. Malaria transmission is 
determined by the frequency of contact between infected mosquitos and humans and vice 
versa. To reduce or interrupt malaria transmission in endemic areas, appropriate vector 
control measures such as insecticide treated bed nets (ITN) and indoor residual spraying 
(IRS) with DDT; and if possible mass drug administration with antimalarials. These 
combined measures were crucial in reducing malaria cases in parts of Asia, particularly in 
India and Sri Lanka [3, 4]. Apart from reducing the risk of having a case of malaria 
developing into a more severe disease, prompt diagnosis and treatment also reduces malaria 
transmission by eliminating the parasite reservoir in the human host [1].  
The malaria parasite was first discovered in 1880 by a French army surgeon, 
Charles Louis Alphonse Laveran [5]. The disease is caused by the protozoan parasite of the 
genus Plasmodium which is transmitted by the Anopheles mosquito vector [6]. Nine 
Plasmodium parasite species are of direct relevance to human health – Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale curtisi, Plasmodium ovale wallikeri, 
Plasmodium malariae, Plasmodium knowlesi, Plasmodium cynomolgi [1, 7-10] and more 
recently, Plasmodium brasilianum [11] and Plasmodium simium [12]. The simian parasites 
P. cynomolgi and P. knowlesi have grown in importance mainly in Malaysia and other parts 
of southeast Asia due to their zoonotic nature [10, 13] without any evidence of natural 




vivax present the most significant threat to human health. P. falciparum, predominantly 
found in the African continent and Asia, accounts for the highest mortality while P. vivax, 
with a wider global distribution, causes significant morbidity due to its ability to cause 
relapsing disease.  
The difference in endemicity of P. falciparum and P. vivax is caused by climate 
effects (primarily temperature) on the parasite development in the mosquito vector. The 
global presence of P. vivax, in sub-Saharan Africa and Asia, is due to the parasite’s ability 
to survive lower temperature and higher altitudes in the mosquito vector [14] and the 
inherent lack of Duffy blood group positive human erythrocytes in the African continent 
which is required for P. vivax infection in erythrocytes [15, 16]. Along with geographical 
differences, the biology of P. falciparum and P. vivax has some important differences. As 
in the less common P. ovale, vivax malaria is characterized by a dormant exo-erythrocytic 
stage – the hypnozoite, which causes relapses sometimes months or years post its primary 
infection in the human host [17]. This dormant form enables the parasites to survive winter 
months when Anopheles mosquitoes hibernate and are not present for malaria transmission. 
These relapses serve as a natural reservoir for transmission since it substantially lengthens 
the period of infection in the host. Another significant difference between P. falciparum 
and P. vivax is the latter’s strict preference in invading reticulocytes [18-23] which makes 
adapting it to in vitro culture challenging. 
1.2 Characteristics of malaria 
1.2.1 Life cycle of the malaria parasite 
The life cycle of the malaria parasite has a complex life cycle alternating between 
two hosts - the female Anopheles mosquito and its definitive human host. Before laying 
eggs, the female Anopheles mosquitoes require blood meals.  During a blood feed, the 
malaria infected-female Anopheles mosquitoes injects Plasmodium species sporozoites 
into the host from its salivary glands. Upon entering the blood stream, the sporozoites 
traverse through host cells before infecting the hepatocytes in the liver within 30 to 60 
minutes post infection. In the human, non-dormant Plasmodium species such as P. 
falciparum (Figure 1.2), these sporozoites develop in the infected hepatocytes to form large 
liver stagess known as the liver-schizonts. These further differentiate into merosomes 




Figure 1.2 Life cycle of the non-dormant malaria parasite (e.g. Plasmodium falciparum). 
During a blood meal, the infected Anopheles mosquito injects sporozoites into the human 
host. The sporozoites infect the hepatocytes and develops into liver schizonts which rupture 
and release merozoites into the blood. The parasites undergo asexual replication in the 
blood where it progresses from the ring stage to the trophozoite and eventually to schizont 
which ruptures to release merozoites back into the blood. Some parasites differentiates into 
the sexual forms of the parasite (gametocytes) which are ingested by the female Anopheles 
mosquito where the gametocytes undergoes fertilization and form infective sporozoites. 
(adapted from www.cdc.gov/malaria). 
In relapsing species in humans such as P. vivax, P. ovale and P. cynomolgi - the 
simian equivalent of P. vivax, apart from the liver- schizonts, they develop dormant forms 
known as hypnozoites which can be reactivated to form liver-schizonts weeks, months or 
years later to complete its life cycle in the host (Figure 1.3) [17, 25, 26]. Once activated, 
the hypnozoites mature into liver-schizonts and the infected hepatocytes burst and releases 
its merosomes into the bloodstream where the released merozoites invade reticulocytes or 







Figure 1.3 Life cycle of the dormant malaria parasite (e.g. Plasmodium vivax). Unlike non-
dormant malaria parasite, when the sporozoites infect the liver cell, it can either develop 
into liver schizonts or dormant hypnozoites which causes relapses after the primary 
infection (adapted from www.cdc.gov/malaria).  
Once in the host red cells, the parasites develop within the membrane-bound 
parasitophorous vacuole (PV) as ring form before it develops into the morphologically 
distinct and proliferative stages – the trophozoite and schizont.   When merozoites in the 
mature schizonts egress, it results in the destruction of the infected erythrocyte membrane 
and releases the parasites to invade new host cells. A small part of this asexual erythrocytic 
population is pre-programmed to undergo gametocytogenesis to produce the sexual forms 
known as the male and female gametocytes. Once mature, these sexual forms are ingested 
by the Anopheles mosquito during their blood meal where they undergo the sporogonic 
cycle to form the diploid zygote (ookinete) in the midgut of the mosquito before developing 
into an oocyst. The motile haploid sporozoites are then released from the oocytes in the 
midgut of the mosquito and passed into the salivary glands where they can be injected into 





Plasmodium species are haploid, undergoing mitotic division when they reside in 
the host. The only diploid stage of its life cycle is the zygote, which is formed when the 
gametocytes fertilize in the mosquito. Genetic recombination and meiosis occur at the 
zygote stage in the mosquito. However, meiosis is short lived and occurs only within a 
few hours of zygote formation followed by mitotic division resulting in the formation of 
sporozoites (Figure 1.4).  Through genetic recombination, various beneficial combination 
of alleles can spread across the parasite population driven by positive selection. This was 
first demonstrated by Walliker et al. in rodent malaria where the progeny of genetic 
crosses between different lines resulted in drug resistance [28]. This similar phenomenon 
was later described in P. falciparum [29, 30].  
 
Figure 1.4 Ploidy in the life cycle of Plasmodium species. Malaria parasites are haploid 
and the only diploid stage in its life cycle is the formation of the zygote, post-gametocyte 
fertilization in the mosquito host. 
1.2.2  Incubation period 
  Incubation period refers to the time between the bite from an infective Anopheles 
mosquito and the first signs of clinical symptoms. Generally speaking, the incubation 
period for human malaria in naïve patients varies between 7 to 30 days. The incubation 
period for P. vivax infections is around 12-17 days, while in P. falciparum it is slightly 
shorter at around 9-14 days. However, the incubation period may be extended in patients 
who have been previously exposed to malaria [31]. 
Recently, increasing cases of zoonotic malaria due to P. cynomolgi and P. knowlesi 




the natural simian hosts and mosquito vectors are at risk of being infected by these simian 
malarias. It has been reported that P. cynomolgi B strain has an incubation period of 10-17 
days [33]. While the incubation period of P. knowlesi in human is between 9 to 12 days 
[34]. . 
1.2.3 Clinical manifestation of malaria 
When a person is first infected with Plasmodium species, a sequence of clinical 
effects may be observed following the bite from an infected mosquito, a pre-patent and 
incubation period before the patient develops symptoms. Pre-patent period refers to the 
asymptomatic period which occurs from sporozoite inoculation in the host and the first 
detection of parasites in the peripheral blood and this usually represents the duration of its 
exo-erythrocytic stage of the parasite.  In general, malaria is a highly preventable and 
curable disease if diagnosed properly and treated correctly and promptly. Based on the 
symptoms observed, malaria can be categorized as uncomplicated or severe. Classic 
clinical symptoms of malaria is closely linked to the erythrocytic cycle of the parasites. It 
consists of a cold stage which is usually accompanied by shivering, then a hot stage where 
fever (which is associated the host inflammatory response to the merozoite egress and 
hemazoin release in the parasites’ erythrocytic cycle) [35] and throbbing headache occurs. 
This is followed by a sweating stage which is associated with profuse sweating and 
declining body temperature. Depending on the species of Plasmodium infected, the cyclical 
occurrence of the symptoms may vary from every 2 days for tertian malaria species such 
as P. falciparum and P. vivax or every 3 days for quartan malaria species such as P. 
malariae [1].  
Severe malaria usually occurs when the primary malaria infection is further 
complicated by organ failures or changes in the patient’s blood or metabolism. These 
include symptoms like cerebral malaria, severe anaemia and metabolic acidosis. If left 
untreated, P. falciparum malaria can quickly develop into cerebral malaria due to the ability 
of P. falciparum infected erythrocytes, especially those with mature trophozoites, to adhere 
to vascular endothelium resulting in the sequestration of infected erythrocytes in the vessels 
of the brain. If not treated promptly will result in coma and death. Young children of less 
than 5 years old, pregnant women, the immunocompromised and elderly are at higher risk 
of developing severe malaria [1]. Patients infected with P. vivax and P. ovale despite having 




primary infection after weeks, months or even years without any symptoms due to the 
presence of hypnozoites which remains dormant until reactivated to continue the parasites’ 
life cycle [1]. Relapses can only be prevented by administration of hypnozoitocidal 
compounds- primaquine and tafenoquine.  
1.3 Antimalarial therapy 
1.3.1 Background 
Antimalarial therapy varies across different malaria-endemic countries, depending 
on the Plasmodium species, the severity of the disease and the parasite’s sensitivity to first 
line therapy [36]. Hence, treatment have to be tailored for effective management of the 
manifestations of malaria.  
For the treatment of uncomplicated P. falciparum erythrocytic stage malaria, the 
first line therapy is usually artemisinin -based combination therapy (ACT), the combination 
of a fast acting artemisinin derivative with a longer acting antimalarial which has a different 
mode of action. Artemisinin derivatives include dihydroartemisinin, artesunate and 
artemether while companion drugs include mefloquine, lumefantrine, amodiaquine, 
sulfadoxine/ pyrimethamine and piperaquine.  Artemisinin was first discovered by Chinese 
scientists in 1971 and introduced to the world in the 1979 as a potential drug to combat in 
malaria  due to its unique mechanism of action and its ability to kill malaria parasites within 
minutes [37]. However, due to patients non-compliance to the 7-day artemisinin 
monotherapy and incomplete parasite clearance due to its short half-life [38], high rate of 
recrudescence was quickly observed. In the 1990s, artemisinin was no longer used as a 
monotherapy and ACTs were introduced.   
Due to the rapid spread of chloroquine resistant P. falciparum, the first line therapy 
for uncomplicated P. falciparum malaria (except pregnant women in their first trimester) 
is the 3-day regiment of ACTs. Commonly used ACTs include artemether with 
lumefantrine, artesunate with amodiaquine, artesunate with mefloquine, 
dihydroartemisinin and piperaquine and artesunate with sulfadoxine-pyrimethamine 
(Figure 1.5). For recurrent P. falciparum infections, the second line treatment which 
involves the co-administration of tetracycline, or doxycycline or clindamycin together with 
either artesunate or quinine for 7-days [36]. For special risk groups such as pregnant women 




quinine with clindamycin. Chloroquine remains as the first line therapy of P. vivax 
erythrocytic stages in areas with no known resistance (e.g. Mexico) [39] while ACTs are 
used in areas with chloroquine-resistant infections (e.g. Indonesia and Papua New Guinea) 
[40]. The 8-aminoquinoline - primaquine is often co-administered with chloroquine for the 
eradication of the dormant forms- the hypnozoites of P. vivax. 
1.3.2 Drugs targeting asexual erythrocytic stages 
The last decade has witnessed major advances in antimalarial drug discovery 
primarily for the erythrocytic stages of the parasites life cycle [41-47]. Due to the almost 
ubiquitous resistance of P. falciparum to chloroquine, ACTs are the preferred mode of 
treatment for uncomplicated P. falciparum erythrocytic infections. The advantages of 
ACTs are their high efficacy, the reduced risk of resistance developing and their rapid 
action in clearing the parasites. Chloroquine remains the first line treatment of P. vivax and 
P. ovale infections in areas with chloroquine susceptible infections while ACTs are used in 
chloroquine resistant infections. Drug screening assays for identification of erythrocytic 
stage active compounds are routinely carried out with P. falciparum as it’s the easiest to 
maintain in vitro and amenable for automated liquid handling procedures for high 
throughput screening. However, erythrocytic stage active compounds in P. falciparum 
sometimes does not translate in efficacy for P. vivax [48] hence more physiological relevant 
erythrocytic stage assay using the sister species- P. cynomolgi, may provide a more 
predictive assessment of clinical outcomes of novel antimalarials treating vivax malaria.  
1.3.3 Drugs targeting sexual erythrocytic stages 
Gametocytes, the sexual stages of the malaria parasite life cycle, are the result of 
the switch from asexual to sexual replication of the parasite in the host. At the late stages 
of the intra-erythrocytic life cycle of the parasite, the schizonts release multiple merozoites 
of which a small ratio (0.2 - 1%) is defined to develop into male and female gametocytes 
[49, 50]. Since 2007, to complement vector control efforts such as the use of insecticide 
treated bed nets (ITN) and indoor residual spraying (IRS) with DDT, malaria eradication 
strategies prioritized antimalarial therapies which combined components capable of 





Figure 1.5 Most commonly used antimalarial drugs used against the three main stages of 
the life cycle of human malaria (liver stage, blood stage and vector stage) (Delves et al.., 
2012). The drugs are colored according to their chemical classes and the stars reflect the 
components of the main ACTs (green: coartem, red: pyramax, orange: eurartesim, blue: 
artesunate-amodiaquine). Drug discovery strategies in the past century focused on using 
molecular approaches where target-based screening led to the identification of novel 
compounds against a validated target. Target-based approaches are dependent on the 
identification of potential inhibitors against protein “targets” which are vital in the 
parasites’ survival. Once the “targets” are selected, protein “binders” are synthesized and 
evaluated in high throughput biochemical screens of chemical or fragment libraries to 
identify molecules with the appropriate binding affinity. 
1.3.4 Drugs targeting exo-erythrocytic stages  
While ACTs have been efficient in eliminating non-relapsing, exo-erythrocytic 




prevent relapses in P. vivax and P. ovale infections. The exo-erythrocytic stages of the 
relapsing malaria include the liver schizonts and the hypnozoites-a non-dividing yet 
metabolically active form of the parasite present in P. vivax and P. ovale in humans as well 
as in P. cynomolgi and P. fieldi in non-human primates. Hypnozoites reactivation is 
responsible for malaria relapse occurring weeks to years following the initial infection [54]. 
The hypnozoite functions as a natural reservoir of the malaria parasite in the liver, which 
impedes eradication. For almost a century, primaquine, a rapidly eliminated 8-
aminoquinoline, is the only licensed drug known to kill both the liver schizonts and the 
hypnozoites. Typically, primaquine is administered together with chloroquine for 14 days 
for chloroquine sensitive P. vivax [36]. 
 Unfortunately, primaquine is not a recommended treatment for pregnant woman 
[55] and patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency [56, 57]. In 
July 2018, another 8-aminoquinoline drug- tafenoquine was approved by FDA as a single 
dose radical cure [58]. However, as with primaquine, tafenoquine cannot be used in patients 
with G6PD deficiency. It took decades for the development of tafenoquine as an alternative 
radical cure due to the lack of predictive in vitro exo-erythrocytic stages for radical cure. 
Most of the in vitro models are unable to capture the full cycle of the the exo-erythrocytic 
stages, including the relapse from the hypnozoites. 
1.4 Antimalarial drug discovery 
1.4.1 Identification of novel antimalarial drugs  
The emergence of Plasmodium species strains with resistance against standard 
antimalarials [59-61] and the need to find better alternatives to the century old radical cure- 
primaquine, provide the main driving forces in malaria drug discovery. New antimalarial 
drugs are often derived from: enhancement of existing drugs, drugs specifically designed 
against a known target and novel active molecules derived from phenotypic high-
throughput screening. 
The ideal antimalarial drug should be active against all developmental stages of the 
parasite which include blood, liver stages and prevents parasite transmission [59]. To 
ensure patients’ compliance, these compounds should preferably be potent enough to elicit 




prophylaxis (SERCaP) treatment [62]. In addition, to ensure accessibility of antimalarials 
even to patients living in poverty, inexpensive production cost is vital.  
However, in the past decade, physiologically relevant phenotypic screens, where 
often the mechanism of action is unknown, is the main contributor to the discovery of new 
antimalarials [63-65]. Phenotypic screening or “whole cell-based” approaches in malaria 
drug discovery involves the evaluation of large compound libraries against the parasite’s 
phenotype, preferably in physiologically relevant environment where the parasite 
manifests. Phenotypic high-throughput screening (HTS) for new drug candidates against 
erythrocytic [43, 63-65] and exo-erythrocytic [42, 66-68] stages of malaria were made 
possible with the advent of automated liquid handling, high content imaging and analysis, 
automated assembly of compound libraries and the minute scale which the assays are 
conducted.   
1.4.2 Phenotypic screens for erythrocytic stages 
  Phenotypic HTS for malaria erythrocytic stage is routinely carried out with P. 
falciparum as they are easily maintained in vitro. As erythrocytic stages are in suspension, 
they are well suited for automated liquid handling and other HTS technologies. In 2008, 
the first large scale phenotypic screen was carried out using asexual P. falciparum 
erythrocytic stages at a single drug concentration [69]. Only around 650 compounds out of 
the 1.7 million compounds screened inhibited parasite growth at less than 100 nM. Since 
then, almost 6 million compounds have been screened where only 0.4% to 1% 
demonstrated activity against growth of asexual P. falciparum erythrocytic stages [70, 71].  
 From the results of these screening efforts, a compound library of 400 unique drug 
entities with antimalarial blood-stage activity was created in 2011 by the Medicines for 
Malaria Venture (MMV). These compounds were selected from hits generated from the 
libraries of St. Jude Children’s Research Hospital, GlaxoSmithKline and Novartis [72]. 
This open access “Malaria Box”, which was made available without cost globally until 
2015, enabled biologists who does not have the capacity to resynthesize compounds to 
participate in the drug discovery process. Developed based on the success of the Malaria 
Box, the Pathogen Box contained 400 diverse compounds which demonstrated activity 
against 13 neglected diseases which includes malaria, tuberculosis and cryptosporidiosis. 




developed which target alternative phenotypes such as invasion [73], gametogenesis [74] 
and “delayed death” [75].  
Phenotypic screens [76, 77] carried out on the Malaria Box and the Pathogen Box 
led to the elucidation of several mechanism of actions of compounds [77, 78] which further 
led to compound optimization for in vivo efficacy. For instance, the 1, 5-naphthyridine 
MMV024101 was first identified from the Pathogen Box with submicromolar potency 
against P. falciparum. This paved the way for structure-activity relationship optimization 
which led to compounds which enhanced in vivo efficacy in the humanized P. falciparum 
mouse efficacy model.   [77].  
1.4.3 Phenotypic screens for exo-erythrocytic stages 
While initial HTS efforts were mainly targeted on the erythrocytic stages of P. 
falciparum, recent progress has been in the development of HTS to identify drugs which 
are active against the exo-erythrocytic stages (also known as liver stages) of the parasite 
life cycle. Since the establishment of the first exo-erythrocytic stage screen on non-dormant 
Plasmodium species [42], various groups have developed various exo-erythrocytic assays 
which utilized sporozoites infection of rodent malaria to either in vivo or in vitro cultured 
primary hepatocytes [66, 79]. False negatives and false positives may result in HTS exo-
erythrocytic stage screens which utilizes rodent parasites as they may not show similar 
response as the human parasites with the compound of interest. Most HTS exo-erythrocytic 
stage screens are two dimensional (2D) and utilizes antibody staining of malaria parasites 
in the infected hepatic cells that requires several liquid-handling wash steps which may 
sometimes result in the loss of infected hepatic cells. Alternatives to antibody staining of 
parasites is the use of transgenic parasites [80] which either stably expresses fluorescent 
reporter protein or luciferase [65, 67] which often lead to a more robust and higher 
throughput exo-erythrocytic stage screen. 
P. vivax and P. ovale are the only human malaria species which form dormant forms 
known as the hypnozoites which can reactivate randomly weeks, months or years later 
through mechanisms not currently well understood. In order for malaria eradication, drugs 
which show activity against these hypnozoites (radical cure) are required.  
 The typical in vitro radical cure screens utilize standard 2D primary hepatocyte 




are not ideal replacements for primary hepatocytes, since they differ in gene expression, 
metabolic pathways, and lack some critical cellular functions. Hepatic cell lines 
occasionally produce contradictory results to what is observed with primary hepatocytes 
[82], although successful but limited infection of HepG2-A16 and HCO4 cell lines have 
been reported with P. vivax [25, 83-85] and P. falciparum [85, 86]. Noteworthy, some drugs 
such as the 8-aminoquinolines (primaquine and tafenoquine) requires processing by hepatic 
cytochrome P450 (CYP450) [87] to be active which is often lost in 2D cultures. In the past 
decade, different strategies have been devised to prolong the viability and functions of 
primary hepatocytes in culture. Some have already been adapted to malaria research, such 
as the innovative in vitro methods established to maintain the exo-erythrocytic parasite in 
a monolayer culture using a Matrigel matrix [88] and more recently, micropatterned co-
cultures (MPCCs) model [89, 90], and collagen-treated 384-well plates comprising a 
micro-physiological environment [68]. In addition, in vivo human liver-chimeric mice 
models were also developed [91].  
While 2D exo-erythrocytic phenotypic assays are relatively cost effective and 
amenable to HTS technologies, their cellular responses and phenotypes does not necessary 
recapitulate the pathology of the disease in the host [92]. Despite the limitations, these 2D 
exo-erythrocytic phenotypic assays were useful in compounds active against the exo-
erythrocytic stages. The first non-8-aminoquinoline compounds, KAI407 and KDU691, 
were first identified through such 2D assays to be active against the dormant hypnozoites 
[93] but failed as radical cure in the simian in vivo model [94].  
Despite animal models being an important aspect in drug discovery, there is a 
demand for more physiologically predictive models which translate to host biology. Over 
the past decade, there is an increase in the development of three-dimensional (3D) tissue 
models [95] which are commonly referred to as spheroid or organoid.  
In the presence of microenvironment components such as extracellular matrix 
(ECM) proteins or partner cells, single cells have the ability to self-aggregate to form 
spheroids and spheroids from different types of cells have been reported [96, 97]. 
Physiologically, spheroid models are better than 2D cell culture models in predicting drug 
efficacy in the human. Various methods have been developed for the formation of 
spheroids. They include the use of solid scaffold [98-100], bioreactor [101, 102], hanging 




1.5 Plasmodium vivax 
1.5.1 Background 
The first report of this human tertian parasite was in 1880 by the French army 
surgeon, Louis Alphonse Laveran [5] where he unknowingly witnessed the exflagellation 
of a male gametocyte in the blood of febrile patients in Algeria. Of the nine Plasmodium 
species affecting humans, P. vivax is associated with high morbidity while P. falciparum 
is associated high mortality [1, 109]. While P. falciparum is prevalent in sub-Saharan 
Africa, P. vivax is the dominant species in the Americas, Southeast Asia and eastern 
Mediterranean and in 2016 around 8.5 million new cases of P. vivax were reported globally 
[1]. It was suggested that the activation of the dormant hypnozoites accounts for 90% of 
relapsing cases of P. vivax globally [110]. 
Unlike P. falciparum infections, the level of parasitemia in P. vivax infections is 
typically low partly due to the parasite’s strict preference for reticulocytes [111] which are 
immature red blood cells formed in the bone marrow after enucleation and released into the 
circulation (~1-2%). Even though other Plasmodium species such as P. falciparum 
preferentially invade reticulocytes, they are still able to invade mature erythrocytes (which 
has facilitated the establishment of continuous culture in this species). The majority of P. 
vivax patients are asymptomatic with sub-microscopic level of parasitemia [112, 113] 
which continues to rapidly produce infective gametocytes for transmission [114]. Such 
sustained transmission, its ability to relapse from dormant liver hypnozoites [54] and its 
increasing resistance to its first line treatment- chloroquine [61, 115], makes controlling 
and eliminating P. vivax challenging. 
1.5.2 Distinct biology of P. vivax 
 Host cells infected by some malaria parasites exhibit various morphological 
features which are distinct for certain species to facilitate its survival in different 
environment. In the late stages of P. falciparum, they form knob like protrusions on the 
infected host cell which is involved in cytoadherence [116], while  P. vivax infected 
reticulocytes are usually enlarged and exhibit unique Schüffner’s dots associated with 
caveolae-vesicle complexes which are suggested to be crucial in the parasites nutrient 
uptake or release of waste metabolite from the parasite infected host cell [117, 118]. 




clearance as the parasite matures, while increase in the deformability of P. vivax infected 
reticulocytes [119] has been associated with the parasite’s ability to avoid splenic clearance 
and remain in circulation. Gametogenesis between the two species is also markedly 
different. P. falciparum gametocytes appear after 10 days after first appearance of asexual 
stages while P. vivax gametocytes are known to appear as early as 3 days post observation 
of its asexual stages [120]. The gametocytes of P. falciparum are noticeably different from 
their asexual stages is grouped to five morphologically different developmental stages 
[121] with the characteristic crescent shaped gametocytes in stage VI [122]. The 
gametocytes of P. vivax have a distinctly round morphology which fills up the majority of 
the infected host cell.   
The characteristic feature of P. vivax is its ability to relapse from dormant exo-
erythrocytic stages known as the hypnozoites [123]. The latter is triggered by unknown 
signals which activate weeks or months after primary infection to cause malaria relapse. 
The timing and frequency of these relapse varies on the geographic origin of the strain 
where strains from temperate regions are associated with longer relapse periods as 
compared to strains from tropical regions [54, 124]. 
1.5.3 Rising drug resistance of P. vivax 
 Resistance is the reduction in effectiveness of an anti-infective agent in curing a 
disease or condition. Emergence and spread of drug resistance in malaria is a major threat 
in the control and elimination of malaria. Chloroquine, a member of the 4-aminoquinolines, 
is widely used for treatment of all human malaria. For the parasite’s survival within the 
host erythrocytes, the parasite degrades the host haemoglobin to yield essential amino acids 
necessary for its growth. During this process, the toxic heme produced is converted to non-
toxic hemozoin crystals by the parasite. Chloroquine inhibits the parasite’s conversion of 
heme to hemozoin, hence leading to the accumulation of toxic heme within the parasite. 
Currently, it is used as the first line treatment for P. vivax erythrocytic stages in 
malaria endemic areas which is sensitive to its effect (e.g. India). Chloroquine resistance in 
P. falciparum was first identified in 1950s [125] in Colombia and the Cambodia-Thailand 
border and it accelerated globally. The first case of chloroquine resistance in P. vivax was 
only reported later in 1989 in Papua New Guinea [126] before rapidly escalating throughout 




elusive in P. vivax, it is well studied in P. falciparum due to the ability to culture the parasite 
in the laboratory and the earlier efforts in studying chloroquine resistance in P. falciparum. 
This lead to the identification of mutations in pfcrt [129-131] and pfmdr [132, 133] 
responsible for conferring chloroquine resistance in P. falciparum. However, mechanisms 
of chloroquine resistance appear to be distinct between P. falciparum and P. vivax despite 
gene synteny between the two species [134].  
In order to answer fundamental questions such as mechanisms of drug resistance in 
P. vivax, the development of a robust continuous culture of its erythrocytic stage parasites 
though vital is fraught with challenges due to the parasite’s strict tropism to reticulocytes. 
Hence the feasibility of establishing a continuous culture using its sister taxon – P. 
cynomolgi [135, 136], especially from a homogeneous isolate, will greatly impact the 
understanding of mechanisms of drug resistance in P. vivax.  
1.6 Zoonosis: a rising threat  
There are more than 100 Plasmodium species, infecting mammals, birds and 
reptiles. There are 9 known species which infects humans and more than 30 species which 
have been reported in non-human primates which includes New and Old World monkeys, 
apes and gibbons. As with human malarias, primate malarias are also transmitted by 
Anopheles mosquitoes.  In the past, numerous studies have been conducted to determine if 
primate malarias were transmissible to man through bites from infected Anopheles 
mosquitoes. They include P. knowlesi [13, 137, 138], P. cynomolgi [139-141] and P. inui 
[142] from Old World monkeys and P. brasilianum [143] and P. simium [144] from New 
World monkeys. This demonstrated with suitable vectors, simian malaria can be naturally 
transmitted to humans. Diagnostic microscopy was the gold standard in the detection of 
malaria. Nonetheless, even with trained clinical microscopists, zoonotic malaria is often 
mistakenly classified as human malaria due to morphological similarities between the 
species. Using polymerase chain reaction (PCR) based molecular diagnostic tests, zoonotic 
transmission of P. knowlesi to humans was identified in 2004 [145] and is now an important 
cause of malaria in Malaysia and Southeast Asia [146-151]. With the development of more 
sensitive and specific detection protocols, other zoonotic malaria has been detected in Asia 




In 1932, Knowles and Das Gupta first identified P. knowlesi and its ability to 
transmit to humans [13]. In their study, they reported its extreme virulence in Indian rhesus 
macaques (Macaca mulatta) while being relatively benign in long tailed and pig tailed 
macaques- Macaca fascicularis and Macaca nemestrina. In the three human subjects 
evaluated, the virulence was varied but all recovered spontaneously without antimalarial 
therapy. In the same year, Sinton and Mulligan noted its distinct stippling in infected 
erythrocytes, the 24-hour erythrocytic (quotidian) cycle and the presence of an accessory 
chromatin dot [153]. With its ability to induce relatively high fevers in humans, “induced 
malaria” therapy using P. knowlesi was explored. In 1935, Van Rooyen and Pile [154] used 
P. knowlesi in the treatment of paresis while Chopra and Das Gupta [155] first 
demonstrated the use of P. knowlesi in the treatment of patients with neurosyphilis in 1936 
where they transferred blood directly from an infected P. knowlesi monkey to the patients.  
The first naturally acquired P. knowlesi infection in human was first reported in 
peninsular Malaysia 1965 by Coatney et al. in 1965 [156] and subsequently, Chin et al.. 
reported the evidence of transmission of P. knowlesi from an infected monkey to man  in 
1968 [138]. This raised the alarm that infected monkeys could now serve as reservoirs for 
malaria in humans. The increase in monkey reservoir in malaria parasites thwarts malaria 
elimination objectives especially when deforestation increases the likelihood of humans 
contracting zoonotic malaria as they are within the vicinity of natural monkey hosts and 
mosquito vectors. Naturally occurring zoonotic cases of P. knowlesi in humans were 
initially thought to be rare until a large cohort of human infections were detected by 
molecular methods in 2004 by Singh et al., P. knowlesi is now the main cause of malaria 
in Malaysia [157].  
 Further evidence of laboratory-acquired mosquito infections of another simian 
malaria, P. cynomolgi in the 1960s, raised the concerns of zoonosis in public health. [139-
141, 158]. However, the first naturally acquired infection of P. cynomolgi in humans was 
only reported in the recent years in peninsular Malaysia [32] and increasing cases were 
subsequently reported in the region [159]. More recently, Imwong et al. demonstrated the 
prevalence of asymptomatic human infection of P. knowlesi co-infected with P. cynomolgi 
in Cambodia [10]. The study also showed genetic similarity between P. cynomolgi and P. 




P. cynomolgi infections in humans may have been occurring for years but might be 
misdiagnosed by microscopy as P. vivax due to their morphological similarities. 
1.7 Plasmodium cynomolgi  
1.7.1  Background 
Plasmodium cynomolgi, a sister taxon to P. vivax, which preferentially infects Old 
World monkeys (e.g. Macaca fascicularis and Macaca mulatta) and is one of the six simian 
malaria known to cause zoonotic infections in humans [32]. It was first identified by Martin 
Mayer in 1907 in Germany in Macaca fascicularis monkeys imported from Java [160]. The 
following year he described the morphological similarities of the simian parasites with P. 
vivax based on microscopy [161]. As with its human counterpart, the P. cynomolgi has a 
forty-eight hour (tertian) life cycle where Schüffner's stippling, amoeboid cytoplasm and 
enlarged infected host red blood cells are noted in its late trophozoite stages. Similarly, in 
the sexual stages, the early gametocytes usually have a large compact nucleus, pronounced 
Schüffner's stippling, not amoeboid and lack a vacuole. When mature, they resemble the P. 
vivax forms with irregular, diffuse nucleus which the microgametocytes are stained a 
reddish-purple in contrast to the light blue stain of macrogametocytes (Figure 1.6).  There 
are various strains of P. cynomolgi known – bastianelli (B) [162, 163], Mulligan (M) [140, 
164], Berok [165], Ceylonensis [166], Gombak [167], Cambodian [168], Smithsonian,  PT 
and RO [169, 170] with the possibility of new strains to be isolated from the wild where 
Anopheles mosquitoes are rampant.  Even though they were originally categorized 
distinctly as B and M strains, the laboratory stocks of the B and M strains from the archive 
sources in the US have recently been reported to be genetically identical [171, 172] 
probably due to a laboratory mix-up in the early 1960s. It has since been suggested to 
rename all B and M strains from the US as the B/M strain [171]. The Berok strain was 
derived from a Macaca mulatta monkey infected with parasites which originated from a 
Macaca nemestrina monkey naturally infected with both P. fieldi and P. cynomolgi. 
Interesting the P. cynomolgi Berok strain appeared to have outgrown P. fieldi in the infected 
macaque [165] despite both species having the same tertian life cycle. In the same study, it 
was noted that the Berok strain apart from being infectious to Old World monkeys, it’s also 





Figure 1.6 Representative erythrocytic stages (ring, trophozoite, schizont and gametocyte) 
of P. falciparum, P. vivax and P. cynomolgi. Erythrocytic stages of P. cynomolgi are 
morphologically similar to P. vivax, in contrast to P. falciparum.   
 
 Apart from the various biologic and morphologic similarities to P. vivax, P. 
cynomolgi has been known to be the closest phylogenetically to P. vivax (Figure 1.7) [171-
173]. The genome size of P. cynomolgi B strain is around 26.3Mb spread across 5,722 
genes predicted on 14 chromosomes with an estimated 40.5% of GC content. 96% of the 
genes are orthologous with P. vivax [172] which further reinforces P. cynomolgi is a good 
model to study P. vivax. In malaria causing parasites, there are two main gene families 
which is responsible for host cell recognition. The erythrocyte binding-like (ebl) genes 
which encodes for Duffy-binding proteins (DBPs) are responsible for binding to Duffy 
antigen receptor for chemokines (DARC) on monkey and human erythrocytes. The 
reticulocyte binding-like (rbl) genes which encodes for normocyte-binding proteins 
(NBPs) in P. knowlesi and reticulocyte-binding proteins (RBPs), encoded by the rbp gene 
family in P. vivax and P. cynomolgi are responsible for the invasion of host erythrocytes. 
Interestingly, it is hypothesized that P. vivax lost its ability to infect Old World monkey 
erythrocyte as it only has one dbp gene while P. cynomolgi which infects both humans and 
Old World monkey erythrocyte has 2 dbp genes [172]. Within the species itself, differences 
were also noted in the rbp genes in the different strains of P. cynomolgi. For instance, the 




Cambodian strain, and the presence of rbp1b gene which is lacking in B and Cambodian 
strains and the presence of rbp2b gene which is present in all three strains [171, 172].  
1.7.2 Erythrocytic stages of Plasmodium species 
 The development of a protocol for the routine continuous culture of P. falciparum 
in 1976 [174, 175] liberated malaria researchers from the reliance on in vivo observations. 
This quickly accelerated P. falciparum research and led to fundamental and translational 
advances throughout the parasite’s life cycle. Unlike P. falciparum which is responsible 
for the highest mortality rates globally, the widespread species P. vivax causes substantial 
[7] morbidity hence the urgent need to devise effective measures to control it. However, 
research on P. vivax remains greatly hampered as attempts to maintain these parasites in 
continuous in vitro culture has been hindered, partly due to its strict restriction to invasion 
of reticulocytes [111, 176, 177]. HTS using in vitro cultured P. falciparum has enriched 
the drug discovery pipeline with a plethora of potential novel lead compounds [178]. HTS 
using P. vivax has been challenging due to limitations in availability and diversity in 
patients’ isolates which renders assay development and standardization impossible. As 
such, selected compounds have been evaluated on primate models and ex vivo drug assays, 
systems not amenable to HTS. To enable sustainable and consistent study of antimalarial 
effect in P. vivax, having a continuous culture P. cynomolgi would be an ideal alternative 
to screen for active antimalarials against P. vivax.    
Following the success of the continuous culture of P. falciparum in 1976, various 
groups invested large amounts of effort in the cultivation of the erythrocytic stages in other 
Plasmodium species, notably P. vivax, P. cynomolgi, P. fieldi and other rodent and simian 
species, especially since this stage is often associated with the clinical symptoms of the 
disease [179] and an area of interest for vaccine development [180]. In the system 
developed by Trager et al. in 1976 for the continuous culture of P. falciparum, the key 
components for successful adaptation were a well supplemented and buffered growth 
medium, compatible serum and naïve erythrocytes with regular refreshment of growth 
medium [174]. The parasites were maintained in petri dishes under these conditions in a 
candle jar where the gas is around 3% CO2 and 15-17% O2. Following the success of 
cultured P. falciparum, few groups were able to successfully adapt other Plasmodium 
species for in vitro cultivation [181, 182]. More recently, the zoonotic malaria species P. 





Figure 1.7. Phylogenetic tree of the Plasmodium genus (Rutledge et al., 2017). 
Phylogenetic tree of the Plasmodium genus depicting the P. malariae clade (red) and P. 
ovale clade (blue) alongside the divergence level of the different species. Values at 
branching points represent bootstrap values. 
1.7.3 The in vitro culture of P. cynomolgi  
 Of interest to this study was the two reports of continuous in vitro-culture of the 
erythrocytic stages of two strains of P. cynomolgi (Berok in one, and Vietnam in the other) 
in the early 1980s [135, 136] which leveraged on the culture system developed for P. 
falciparum. Apart from the different strains used in their studies, the culture conditions 
used were also unique.  
 Nguyen et al. [135] was the first to report the successful continuous culture of P. 
cynomolgi in 1981 where the Berok strain was continuously cultured for up to 6 weeks in 
human serum which supposedly sustained growth better than rhesus serum. Attempts to 
culture the parasites in vitro with human blood proved futile. The cultured parasites 
remained infective in rhesus monkeys and the reduced amoeboid morphology noted in the 
trophozoites in vitro was reversed in vivo. The initial inoculum had to be regularly 




also in a continuous flow method.  Zhou et al. in 1984 [136] demonstrated the continuous 
culture of P. cynomolgi using another strain isolated from Vietnam where routine 
subculture with Macaca mulatta erythrocytes was required to sustain its growth for more 
than 140 days. The culture was able to be reinitiated from a frozen stabilate with no 
apparent difference in amplification.  Unlike the Berok strain, the Vietnamese strain 
retained the amoeboid morphology of the trophozoites in vitro and sustained in culture with 
Macaca mulatta serum.  
The attainment of continuous culture using different strains of P. cynomolgi suggest 
the success in adaptation for continuous culture of Plasmodium species is an eventuality 
when various strains of the parasite are explored with calculated persistence.  
1.7.4 Exo-erythrocytic forms of Plasmodium species 
In 1902, Schaudinn [185] hypothesized that sporozoites infected the erythrocytes 
directly, a concept that was negated in the avian malaria Plasmodium relictum in 1936 
[186] and Plasmodium gallineceum in 1938 [187]. It took another 10 years before Shortt 
and Garnham [188, 189] first described the pre-erythrocytic forms in the liver of monkeys 
infected with P. cynomolgi sporozoites but not erythrocytic stage malaria and was 
reconfirmed in human subjects infected with P vivax [190, 191]  in 1948. Until the late 
1940s it was largely assumed that Plasmodium infections were strictly erythrocytic. It was 
not until 1948 where Shortt and Garnham [192] demonstrated experimentally that a pre-
erythrocytic or exo-erythrocytic stage existed in P. cynomolgi parasites. They were driven 
by the observations made by James in 1931 [193] where he noted that infections initiated 
with  erythrocytic stage parasites were rapidly associated with clinical symptoms and 
parasites could be recovered from peripheral blood while infections from sporozoites 
required an incubation period of several days before any parasites could be detected in the 
blood. From their investigations, Shortt and Garnham concurred that following 
sporozoites-induced infection from infected mosquitoes, parasites were not detected in the 
peripheral blood while for infections induced from infected blood, parasites quickly 
appeared in the circulation.  In addition, infected blood-induced infections could be 
eradicated with drug treatment while sporozoites-induced infections could not. They 
carefully catalogued their observations performing daily liver biopsies of the infected 




cynomolgi in monkeys over a period of 10 days and P. vivax in humans on day 7 post 
sporozoites induced infections [191].  
Following the success of the continuous culture of P. falciparum in 1976, various 
groups invested large amounts of effort in the cultivation of the erythrocytic stages in other 
Plasmodium species, notably P. vivax, P. cynomolgi, P. fieldi and other rodent and simian 
species, especially since this stage is often associated with the clinical symptoms of the 
disease [179] and an area of interest for vaccine development [180]. In the system 
developed by Trager et al. in 1976 for the continuous culture of P. falciparum, the key 
components for successful adaptation were a well supplemented and buffered growth 
medium, compatible serum and naïve erythrocytes with regular refreshment of growth 
medium [174]. The parasites were maintained in petri dishes under these conditions in a 
candle jar where the gas is around 3% CO2 and 15-17% O2. Following the success of 
cultured P. falciparum, few groups were able to successfully adapt other Plasmodium 
species for in vitro cultivation [181, 182]. More recently, the zoonotic malaria species P. 
knowlesi was successfully adapted to continuous culture in human erythrocytes [183, 184] 
Relapse in malaria is referred to as the re-appearance of erythrocytic parasites in 
the host from a sporozoite-induced infection which was previously treated with blood 
schizontocidal therapy [194]. The first recorded history of true relapse in vivax malaria was 
reported by Thayner in 1897 in which a physician experienced several episodes of chills 
almost 2 years post initial infection despite not being re-exposed between the two the 
occurrences [195]. In the early 1900s, experimental evidence of relapse arose when Manson 
[196] and Fearnside [197] independently infected healthy individuals with P. vivax infected 
mosquitoes which resulted in primary infection which was successfully treated with 
quinine. Relapse occurred several months post primary infection for both instances. 
Relapses can only be prevented through proper diagnosis and treatment with 8-
aminoquinoline anti-malarials such as primaquine. Latency period between the primary 
infection and relapse appear to vary on the epidemiology of the disease. In tropical regions, 
the latency period is usually shorter (several weeks) as compared to its temperate 
counterparts (several months) [156].   Apart from the difference geographic zones of P. 
vivax strains which display different relapse patterns, other speculative factors for 




reaction to a mosquito bite [198], stimulus from a febrile illness [199] and the genetically 
pre-determined biological clock of hypnozoites [200]. 
1.7.5 The dormant stages of P. cynomolgi and P. vivax 
As with P. vivax in humans, P. cynomolgi also cause relapses in its simian hosts 
[17, 26, 201]. P. cynomolgi has been instrumental in the discoveries of the exo-erythrocytic 
stages of the parasite since there was no designated P. vivax strain to study the biology of 
liver hypnozoites and schizonts. The first evidence which demonstrated the utility of P. 
cynomolgi as a relevant model for P. vivax research was the study by Shortt et al. in 1948 
[192] where they identified exo-erythrocytic stages of  P. cynomolgi parasites as the cause 
for relapses which is similarly found in P. vivax. The model further proved its importance 
when Eyles et al. first demonstrated the zoonotic potential of P. cynomolgi B strain in 1960 
[139] where the infection in humans retained the tertian periodicity and its distinct 
Schüffner’s stippling in enlarged host infected erythrocytes. Since then, more cases of 
zoonotic transmission to humans were reported [140, 141, 158] where the infections were 
usually low grade. In the early 1980s, Krotoski and colleagues identified that hypnozoites 
were the cause of the relapses using the B strain [26, 202, 203]. Since then, the P. cynomolgi 
B and M strains have been the most characterized strains as they were widely used in 
understanding P. cynomolgi’s sporogonic cycle, structural studies of the exo-erythrocytic 
stages,  and large scale infection studies involving Old World monkeys [156].  
1.7.6 P. cynomolgi in drug discovery 
 Animal experimentation is widely used in biomedical research, especially in 
understanding host-pathogen interactions. Animal studies are usually conducted either 
using rodent or non-human primate (NHP) models. Rodent models make up the majority 
of animal studies as they are relatively inexpensive and easier to handle.  The usefulness of 
the data generated from animal experimentation will depend on the clinical and biological 
relevance of the animal model used. Rodents though useful in the biomedical research, are 
phylogenetically distinct from human [204, 205] are hence not as useful in predicting 
behavioral and biological responses in humans. NHPs are phylogenetically and 
physiologically similar to humans (Figure 1.8) which makes NHP models ideal in studying 






Figure 1.8 Primate phylogenetic tree (Rogers and Gibbs, 2014). Phylogenetic tree 
representing evolutionary relationships among different species of primates. The separation 
of the human lineage diverged from the non-human primate lineage around 9 to 5 million 
years ago.   
 NHP models have been instrumental in malaria research for decades particularly in 
the identification of hypnozoites in relapsing malaria. These were first identified in NHP 
models where rhesus macaques were experimentally infected with P. cynomolgi [26] and 
subsequently in chimpanzees infected with P. vivax. Apart from understanding the biology 
of malaria parasites, NHP models are crucial in preclinical development phase of drug 
discovery where potencies of novel antimalarial drugs are assessed as they provide a more 
accurate prediction of human efficacy and pharmacokinetics [93, 94, 206-208]. P. 
cynomolgi was vital in the development of primaquine as radical cure [207] and remains 




infections in NHP models [209, 210] and in vitro-cultured hypnozoite model [88, 211]. 
Development of in vitro primary hepatocyte culture models which sustained the cultivation 
of both P. cynomolgi exo-erythrocytic stages enabled screening of novel anti-
hypnozoitocidal drugs [93].  
1.8 Aims and objectives of this thesis 
In this study, the main objectives were to address the fundamental challenges in P. 
vivax drug discovery- the lack of (i) in vitro culture of erythrocytic stages for HTS screening 
and (ii) predictive radical cure model to evaluate anti-hypnozoitocidal drugs. These were 
accomplished by using P. cynomolgi as the surrogate model to investigate antimalarial 
effects in all stages (erythrocytic and exo-erythrocytic) of the P. vivax parasite in the host.  
The first set of results (chapter three) demonstrates the establishment of a robust in 
vitro culture of P. cynomolgi erythrocytic stages which retained its infectivity in 
mosquitoes. This scalable continuous culture was also amenable for HTS drug screening 
for antimalarials. In addition, to further develop the continuous culture of P. cynomolgi as 
a tool for future techniques such as genotyping and understanding of drug resistance, a 
homogenous isolate from the continuous culture was isolated.  
Chapter four then demonstrates the establishment of a novel P. cynomolgi infected 
3D spheroid model for in vitro radical cure compound profiling. A new method to infect 
the hepatocytes in suspension prior to 3D spheroid formation to increase infectivity was 
established, where the infected spheroids were able to recapitulate the entire life cycle of 
the exo-erythrocytic stages of the parasite which included the transition from liver 
merosomes to the erythrocytic stages. More importantly, this 3D spheroid model was easily 












This section comprises of general cell culture techniques for malaria and 
experimental details for specific experiments in following chapters of this thesis. The time 
line (Table 2.1) and experimental details are categorized as:  
2.1  Continuous in vitro culture of Plasmodium cynomolgi Berok K4 erythrocytic stages 
2.2  Establishment of a 3D hepatic spheroid model to study the exo-erythrocytic stages 
of Plasmodium cynomolgi 












Table 2.1. Timeline of experiments carried out in this study
Description 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9
2.1 Continuous in vitro culture of Plasmodium cynomolgi  Berok K4 erythrocytic stages
Optimization of culture conditions and cryopreservation of P. cynomolgi  Berok K4 in vitro  culture
Transmission study of P. cynomolgi  Berok K4 strain
Phentotypic and genotypic characterization of P. cynomolgi  Berok K4 in vitro  culture
Clonal selection and cryopreservation of P. cynomolgi  Berok K4-A7 strain
Drug susceptibility testing with P. cynomolgi Berok K4 in vitro  culture
Serum substitution of clonal P. cynomolgi  Berok K4-A7 strain
Whole genome sequencing of clonal P. cynomolgi  Berok K4-A7 strain
2.2 Establishment of a 3D hepatic spheroid model to study exo-erythrocytic stages of Plasmodium cynomolgi
Optimisation and characterization of simian spheroid model for infection with P. cynomolgi  sporozoites
Optimisation of infected simian spheroid model for drug screening with P. cynomolgi  sporozoites







Continuous in vitro culture 
of Plasmodium cynomolgi 




2.1.1  Ethical committees and animal welfare 
Macaca fascicularis (cynomolgous monkeys) were maintained at the Novartis 
Laboratory Animal Services, New Jersey, U.S.A., (Novartis-LAS) and SingHealth 
Experimental Medicine Center, Singapore. Both institutions were audited and approved by 
the Novartis Animal Welfare Compliance. All animals were housed in accordance with the 
Guide for the Care and Use of Laboratory Animals and the Association for the Assessment 
and Accreditation of Laboratory Animal Care (AAALAC) Standards. All studies were 
approved by the Novartis Ethical Review Council and Novartis Institutional Animal Care 
and Use Committees prior (IACUC) to study initiation. Additionally, work at SingHealth 
was approved by the SingHealth IACUC. Clinical samples utilized in this study were 
collected from P. vivax infected malaria patients attending the clinics of the Shoklo Malaria 
Research Unit (SMRU), Mae Sot, Thailand, under the following ethical guidelines in the 
approved protocol; OXTREC 45-09 (University of Oxford, Centre for Clinical Vaccinology 
and Tropical Medicine, UK) and MUTM 2008-215 from the ethics committee of Faculty of 
Tropical Medicine, Mahidol University. 
 
2.1.2  P. cynomolgi B, M and Berok strains 
Three P. cynomolgi lines were used in this study, the Berok strain [212], the B strain 
(P. cynomolgi bastianelli) [162], and M strain (P. cynomolgi mulligan) [140, 164]. The “B” 
strain or P. cynomolgi bastianellii was isolated by Garnham in 1959 from an infected M. 
fascicularis (previously named M. irus) near Kuantan, in the East Coast of Malaysia [162]. 
The P. cynomolgi Berok strain originated from Perak, Malaysia, where it was isolated from 
an infected M. nemestrina monkey [212]. The Berok strain used in this study consisted of a 
single cryopreserved 1 mL sample passage through Aotus monkeys and dated as 1998. The 
sample was thawed-out as described below and washed prior to a tail-vein administration to 
a splenectomised M. fascicularis monkey. The P. cynomolgi “M” strain was first described 
by Mulligan in 1935 [164] and later shown to be transmitted to man 1961 [140]. The B and 
M strains were provided by Associate Professor Bruce Russell (University of Otago) and 




2.1.3  P. cynomolgi base medium composition for continuous culture 
RPMI 1640 (Roswell Park Memorial Institute) supplemented with GlutaMAX (Cat. 
No. 61870-036, Gibco) containing 30 mM HEPES (Cat. No.  H4034, Sigma-Aldrich), 0.2% 
(w/v) D-glucose (Cat. No. G7021, Sigma-Aldrich) and 200 M hypoxanthine (Cat. No. 
4010BC, Calbiochem). Either 20% (v/v) heat inactivated M. fascicularis serum or 20% (v/v) 
heat inactivated fetal bovine serum (Cat. No. 16000-036, Lot no. 1891471, Gibco) was 
added prior to use.  
 
2.1.4  Macaque naïve blood and serum extraction and preparation  
M. fascicularis naïve erythrocytes and serum were obtained from SingHealth 
Services Pte Ltd. Blood was collected by venous puncture into lithium heparin vacutainers 
(Becton-Dickinson). The blood collected was adjusted to 50% haematocrit with RPMI 1640 
(Roswell Park Memorial Institute) supplemented with GlutaMAX (Cat. No. 61870-036, 
Gibco) containing 30 mM HEPES (Cat. No.  H4034, Sigma-Aldrich) before passing through 
pre-equilibrated non-woven filters (Antoshin) to deplete leukocytes. The leukocyte-free M. 
fascicularis naïve erythrocytes were pelleted by centrifugation at 1800 rpm (650 rcf) for 5 
min (Eppendorf 5804R) at room temperature (RT), washed thrice in RPMI 1640 
supplemented with GlutaMax and 30 mM HEPES before it was stored at 4C in the same 
medium at 50% haematocrit until use. For collection of M. fascicularis serum, the blood 
was collected by venous puncture into SST serum separation vacutainers (Becton-
Dickinson), inverted gently 5 times and allowed to clot in a vertical position. The tubes were 
then centrifuged at 3000 rpm (1180 rcf) for 10 min at room temperature. The M. fascicularis 
serum supernatant was collected and heat-inactivated for one hour at 56C and stored at -
20C until use.  
 
2.1.5  Cryopreservation of P. cynomolgi Berok K4 and K4-A7 erythrocytic stages  
P. cynomolgi parasite culture of predominantly ring stages were pelleted by 
centrifugation at 1800 rpm (650 rcf) for 5 min at room temperature (RT), the supernatant 
discarded. 0.33 time the volume of the packed red blood cell pellet of Glycerolyte 57 
35 
 
(Fenwal) was added drop wise at 30 seconds (s) interval while gently shaking the tube to 
ensure contents were well mixed. It was then left to incubate for 5 min at RT. 1.33 times the 
volume of the packed red blood cell pellet of Glycerolyte 57 (Fenwal) was next added drop 
wise at 15 seconds interval while gently shaking the tube to ensure contents were well 
mixed. The P. cynomolgi parasite-Glycerolyte mixture were then aliquoted to properly 
labelled sterile cryovials and at kept in the Mr. Frosty™ freezing container overnight at -
80C before the vials were transferred for long term storage in LN tank.  
 
2.1.6  Thawing of frozen stock and routine in vitro parasite growth in cynomolgous 
RBCs with either M. fascicularis serum or fetal bovine serum 
P. cynomolgi Berok K4 or K4-A7 parasite cultures were started from 1 mL stabilate 
cryopreserved samples. The frozen samples were thawed-out using the sodium chloride 
method [213]. Briefly, sequentially decreasing concentrations of sodium chloride (NaCl) 
were added starting with 0.2 mL of 12% (w/v) NaCl added slowly drop-wise with gentle 
mixing, incubated at room temperature for 5 min without shaking, and further diluted in 10 
mL of 1.6% (w/v) NaCl added drop-wise with gentle mixing. The samples were pelleted by 
centrifugation at 1800 rpm (650 rcf) for 5 min (Eppendorf 5804R)  at RT, the supernatant 
discarded and samples were subjected to a final wash in 10 mL P. cynomolgi base medium 
added drop-wise with gentle mixing, pelleted by centrifugation at 1800 rpm (650 rcf) for 5 
min at RT (Eppendorf 5804R) and re-suspended in complete medium comprising of P. 
cynomolgi base medium supplemented with either 20% (v/v) heat inactivated macaque 
serum or 20% (v/v) heat inactivated fetal bovine serum (Cat. No. 16000-036, Lot no. 
1891471, Gibco).  
Naïve macaque blood was added to a final haematocrit of 5%. The parasites were 
initially cultured in plates in a modified candle jar (Stemcell technologies 27310) at 37C 
comprising of about 3-5% CO2, and 8-10% O2 [214, 215]. Cultures were monitored daily 
by Giemsa-stained thick and thin smears by microscopy and parasitemia adjusted between 
1% and 5% for routine culture. The medium was changed every other day. To enable larger 
culture of scale for P. cynomolgi Berok K4 and K4-A7 erythrocytic stages, the cultures were 
adapted to trimix gas (5% CO2, 5% O2, 90% N2). All other conditions were the same as for 
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the modified candle jar. For cultures in trimix gas, the parasites were cultured and gassed in 
appropriate non-vented cell culture flasks.  
 
2.1.7  Determination of parasitemia via light microscopy of Giemsa stained slides 
The Giemsa stain, consisting of eosin and methylene blue, is used as the gold 
standard for the diagnosis malaria in blood smears. Parasitemia is the quantification of the 
percentage of red blood cells which are parasitized and the haematocrit of the culture refers 
to the amount of red blood cells (usually in v/v percentage) present in the culture. Thick and 
thin film smears were prepared with 5 µL of packed red blood cells from the culture for 
Giemsa staining. The thin film smears of were fixed with 100% methanol (Cat. No. A412-
4, Fisher Scientific) and dried before both the thick and thin film smears were immersed in 
10% Giemsa solution (Cat. No. 352603R, VWR) in phosphate-buffered saline (pH 7.2) 
(PBS) for 30 min prior rinsing.  Parasitemia was determined from the thin film under light 
microscope (NIKON YS100) with 1000X magnification with oil immersion lens. The 
number of red blood cells per milliliter (mL) was determined using a hemocytometer 
(inCYTO DHC-N01 Neubauer Improved) to be in the range of 0.4 x 107 to 0.6 x 107 
RBCs/mL. The number of infected red blood cells (iRBC)/ L was calculated using the 
formula: (% Parasitemia)/100 x 5 x 106 iRBC/ L. 
 
2.1.8  Parasite synchronization by 5% sorbitol 
P. cynomolgi parasite cultures at predominantly ring stages were pelleted by 
centrifugation at 1800 rpm (650 rcf) for 5 min (Eppendorf 5804R) at RT, the supernatant 
discarded and samples were suspended in 5% sorbitol (Cat. No. S1876, Sigma-Aldrich) to 
give a final hematocrit of 20%. After incubating for 15 min at 37C, the parasite culture was 
pelleted by centrifugation at 1800 rpm (650 rcf) for 5 min at RT (Eppendorf 5804R), the 
supernatant discarded and samples were washed with at least twice with P. cynomolgi base 
medium before it was returned to culture in P. cynomolgi complete medium in either (20% 
(v/v) M. fascicularis serum or 20% (v/v) heat inactivated fetal bovine serum (Cat. No. 
16000-036, Lot no. 1891471, Gibco) in trimix gas (5% CO2, 5% O2, 90% N2) at 37C. 
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2.1.9  Enrichment of P. cynomolgi Berok K4 late stages using MACS LD Columns 
The infected RBCs of in vitro P. cynomolgi Berok K4 were first synchronized with 
5% sorbitol (Cat. No. S1876, Sigma-Aldrich) before they were matured to late stages and 
enriched using MACS LD columns (Miltenyi Biotech Asia Pacific Pte Ltd). The MACS LD 
column (Cat. No. 130042901, Miltenyi Biotec,) affixed to the MidiMACS Seperator (Cat. 
No. 130042302, Miltenyi Biotec) was pre-primed with P. cynomolgi Berok K4 base 
medium. The parasite culture was first pelleted by centrifugation at 1800 rpm (650 rcf) for 
5 min at RT (Eppendorf 5804R) before the pellet was resuspended to 20% haematocrit with 
P. cynomolgi Berok K4 base medium before it was transferred to the pre-primed MACS LD 
column. The flow through containing uninfected red blood cells and early stages of the 
parasite were discarded. The retained hemozoin containing late stages (mid-late 
trophozoites, schizonts) magnetized to the LD column was eluted and washed three times 
with RPMI-1640 supplemented with 30 mM HEPES before the concentrated late stages 
were returned to culture. 
 
2.1.10  Clonal isolation of heterogeneous population of P. cynomolgi Berok K4 by 
dilution method 
  A mixed stage culture of the heterogeneous P. cynomolgi Berok K4 continuous 
culture was used for the selection of homogeneous parasite populations (clones) by limiting 
dilution in a 96-well plate. The parasite culture was adjusted to 0.5% parasitemia for column 
1 of the plate and was serially diluted 10-fold across the plate to from column 1 to column 
11. Column 12 served as a background control of uninfected RBCs.  In each well of parasite 
dilution, it contained 180 L of P. cynomolgi complete medium containing 20% (v/v) of 
heat inactivated M. fascicularis serum at 1.25% haematocrit (Appendix A). Apart from 
medium refreshment every alternate day, the gas chamber containing the 96-well limiting 
dilution plate was also gassed with trimix gas every alternate day and 0.1% haematocrit was 
added to each well every bi-weekly to account for RBC lysis.  
20 L aliquots of the plate was first sampled for flow cytometry analysis (FACS) on 
Day 20 post seeding for determination of total percentage of parasites per well and 
subsequently repeated every 3 weeks until clones were noted in respective wells. The 20 µL 
aliquot from each well was harvested into a small curved-bottom tube (Micronic) before 0.5 
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L of 1 mg/mL dihydroethidium (Cat. No. D7008, Sigma-Aldrich) and 1 L of 800 M of 
Hoechst 33342 (Cat. No. B2261, Sigma-Aldrich) was added and made up to 100 L with 
PBS. The tubes were incubated in the dark at room temperature for 20 min. After incubation, 
400 L of cold PBS was added. 100,000 events were acquired with an Accuri C6 (BD 
Biosciences, US). The data were analyzed using FlowJo software (Tree Star Inc.). 
Giemsa smears were sometimes carried out to determine the total percentage of live 
parasites in random wells for verification of FACS results. The respective clones (K4-A5, 
K4-B5, K4-G5, and K4-A7) identified from the positive FACS readout from Day 55 were 
isolated and amplified in continuous culture before cryopreservation and further studies. 
 
2.1.11  Serum substitution of clone P. cynomolgi Berok K4-A7 to complete medium 
containing 20% (v/v) heat inactivated fetal bovine serum 
To minimize the amount of M. fascicularis naïve blood needed for the continuous 
culture of P. cynomolgi Berok K4-A7, an asynchronous culture K4-A7 which was 
amplifying steadily in complete medium containing 20% (v/v) heat-inactivated M. 
fascicularis serum was sub-cultured and maintained in complete medium containing 10% 
(v/v) heat-inactivated M. fascicularis serum and 10% (v/v) heat-inactivated fetal bovine 
serum (Cat. No. 16000-036, Lot no. 1891471, Gibco). After 2 weeks of steady growth in the 
complete medium containing the mixed serums, the culture was subsequently maintained in 
complete medium containing 20% (v/v) heat-inactivated fetal bovine serum (Cat. No. 
16000-036, Lot no. 1891471, Gibco). 
 
2.1.12  Micropipette aspiration and RBC sphericity measurement (collaboration with 
National University of Singapore (NUS)) 
The micropipette aspiration technique was modified from Hochmuth, 2000 [216]. 
Briefly, 1 µL of packed red blood cells containing approximately 1% parasitemia and 
suspended in 1 mL PBS (1% BSA). The samples were mounted onto the Olympus IX71 
Inverted Microscope. A borosilicate glass micropipette (~1.5 µm inner diameter) was used 
to extract the cell membrane under a negative pressure at a pressure drop rate of 0.5 pa/s. 
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The corresponding cell membrane deformation was monitored using a 100X oil immersion 
lens. The cell membrane deformation was recorded using the QColor5 High Resolution 
Color CCD Digital Fire Wire Camera (Olympus) and processed by QCapture Pro 6.0 
(Olympus). The cell membrane shear modulus was calculated using the hemispherical cap 
model [216]. To quantify the binding force between uninfected RBC and a rosetting infected 
RBC (iRBC), a double pipette aspiration method was used [217]. A rosette was held by a 
micropipette (diameter = 2.0 ± 0.2 µm). A second micropipette was used to aspirate the 
uninfected red cell at increased levels of pressure. The force (F) to detach the red cell from 
the iRBC was calculated a sF = πr2 × P; where r is the inner diameter of the second 
micropipette, and P is the pressure required for cell detachment. The aspiration pressure was 
measured by a pressure transducer (P61 model, Validyne Engineering) and recorded by 
USB-COM Data logger (Validyne Engineering). The process was recorded using a Dual 
CCD Digital Camera DP80 (Olympus®) at one frame/s. Recorded images were analyzed 
with CellSens Dimension (Olympus®). 
 
2.1.13  Atomic force microscopy (collaboration with NUS) 
 P. cynomolgi Berok K4 continuous culture was harvested at the trophozoite stage 
and 200 µl of the blood medium mixture was supravitally stained with 1 µL of DAPI, for 15 
min in an incubator and prepared as smears (unfixed and air dried) for atomic force 
microscopy (AFM). At least 20 iRBCs from each isolate and cell type was scanned using 
AFM. We were able to conduct serial measurements (with AFM, then and with Giemsa) by 
using a copper microdisk grid (H7 finder grid, SPI Supplies, PA) attached underneath the 
glass slide allowing us to locate and image the same cell. These thin smears were first AFM 
scanned by a Dimension 3100 model with a Nanoscope IIIa controller (Veeco) using tapping 
mode. The probes used for imaging were 125 µm long by 30 µm wide single-beam shaped 
cantilevers (Model PPP-NCHR-50, Nanosensors) with tip radius of curvature of 5-7 nm. 
Images were processed using the Nanoscope 5.30 software (Veeco).  
 
2.1.14  Scanning electron microscopy of infected RBCs  
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Sorted cells coated on poly-lysine (Sigma) glass coverslips were fixed in 2.5% 
glutaraldehyde, washed, and treated with 1% osmium tetroxide (Cat. No. 18612, Ted Pella 
Inc.) before critical point drying (CPD 030, Bal-Tec). Glass coverslips were sputter-coated 
with gold in a high vacuum (SCD005 sputter coater, Bal-Tec) and imaged with a field 
emission scanning electron microscope (JSM-6701F, JEOL) at an acceleration voltage of 8 
kV[218]. 
 
2.1.15  Image stream analysis of rosetting (collaboration with NUS) 
We determined the percentage of rosetting of P. cynomolgi Berok K4 iRBCs by 
image stream analysis using a method adapted from Lee et al. 2014 [219]. Briefly iRBCs 
stained with Hoechst and dihydroethidium were suspended in PBS to a haematocrit of 2% 
and were assayed with the ImageStream 100 (Amnis, Seattle, WA) fitted with a 60X 
objective. At least 200 untreated parasites for each single-stain condition were used to create 
a compensation matrix. During screening, 10,000 parasites were acquired and gated using 
the technique adopted from Malleret et al. [220] along with the added selection of cells that 
were not singlets (one or more cells adhering to an infected cell staining positive for 
Hoechst). Analysis was performed with the IDEAS software (version 4.0). 
 
2.1.16  Rosetting wet-mount (collaboration with Singapore Immunology Network 
(SIgN)) 
As previously described [221], the P. cynomolgi Berok K4 culture was sampled at 
ring, trophozoite and schizonts stages of its life cycle. To determine the number of rosettes 
and live parasites, the respective sampled culture suspension was stained with Giemsa (final 
concentration of 5%) for 15 minutes. A minute volume of this suspension was used to make 
a wet mount with 22 x 32mm (0.17mm thickness) glass cover slip. This wet mount was 
examined immediately with light microscope under oil immersion magnification. Rosetting 
rate was evaluated by examining 200 iRBCs.  
 
2.1.17  DNA extraction, PCR amplifications and sequencing  
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For the comparison of genes rbp1b, rbp 2a and rbp2b via PCR amplifications 
between heterogeneous P. cynomolgi Berok K4, clonal P. cynomolgi Berok K4-A7 and P. 
cynomolgi B strain, 200 L packed cell volume (pcv) of the respective cultures was used for 
DNA extraction using DNA Blood Mini kit (Qiagen, cat. No. 51104). The respective RBP 
primers were designed based on the following published sequences - Pcy RBP2a strain B 
Chromosome 8 GI: 457870682, Pcy RBP2b Berok JQ422039.1, Pcy RBP1b Berok 
JQ422038.1, Pcy RBP2a B strain GI:389585944, Pcy RBP2a Chromosome 14 strain M GI: 
LT841392.1 and Pcy RBP2a Chromosome 4 strain M GI: LT841382.1 
 
2.1.18 Preparation of P. cynomolgi Berok K4-A7 for whole genomic sequencing 
For extraction of genomic DNA, the P. cynomolgi Berok K4-A7 culture was 
amplified to 2 billion parasites (i.e.  8 % parasitemia in 100 mL complete medium at 5% 
haematocrit) before parasite extraction was carried out from the iRBCs via saponin lysis 
(0.15% saponin and 0.1% bovine serum albumin fraction V in phosphate buffered saline) 
Briefly, after centrifugation at 1800 rpm (650 rcf) for 5 min at RT (Eppendorf 5804R) the 
pellet was reconstituted to 10% haematocrit with P. cynomolgi base medium before the 
required amount of saponin lysis buffer was added on ice. Upon lysis of red blood cells, 
indicated by a clear red supernatant, the lysed cultures were centrifuged at 1800 rpm (650 
rcf) for 5 min at RT (Eppendorf 5804R) and the parasite cell pellets were rinsed twice in 
chilled PBS. As previously described [222], the DNA was isolated from the parasite cell 
pellets using a Blood and Cell Culture DNA Mini extraction kit (Cat. No. 13323, Qiagen).  
 
2.1.19 P. cynomolgi Berok K4-A7 whole genome sequencing using Oxford Nanopore  
Plasmodium cynomolgi gDNA (2.5 µg) was input to the Oxford Nanopore, SQK-
LSK308 (1D2) library preparation workflow according to manufacturer’s instructions. 
Prepared library of 355.2ng was loaded onto a FLO-MIN107 flowcell on the GridION 
instrument, running MinKNOW v2.1 with live 1D basecalling via Guppy v1.5.1. The library 
was sequenced for 48 hours, generating a total of 596,000 reads totalling 2.54GB, with 
360,387 reads having Q≥ 7, totalling 1.99GB. FASTQ files containing 596,000 total 
sequences were used for de novo assembly using Canu (a fork of the Celera Assembler with 
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specific adaptations for Oxford Nanopore). The assembly consists of 44 contigs totalling 
36,839,098bp. To check on the quality of the assembly, the reference genome B strain of 
the P. cynomolgi (RefSeq assembly accession GCF_000321355.1) was used. Mummer4 was 
used to align the de novo assembly to the reference genome and 90.9% of the reference 
genome could be mapped to portions of the de novo assembly with an average identity of 
88.66%. 
 
2.1.20  PCR Free genomic DNA library for short read sequencing (Illumina)  
Genomic DNA (2µg) was sheared using Covaris S2 sonicator in 52.5μl volume using 
the following parameters: 10% duty cycle, intensity 4 and 200 cycles per burst for 45 
seconds to generate DNA fragments that are enriched for 550bp in length. Whole-genome 
sequencing libraries were prepared using Illumina TruSeq® DNA PCR-Free library prep kit 
according to manufacturer’s instructions. The libraries were re-suspended in 30 µl of re-
suspension buffer. Concentrations of the purified libraries were estimated using the High 
Sensitivity DNA kit (Agilent Technologies, Santa Clara, CA). Subsequently qPCR 
quantitation was performed using KAPA library quantification kit to ascertain the loading 
concentration. The resultant libraries were sequenced using Illumina Miseq to generate indexed 
paired-end reads of 2 × 251bp at a sequencing depth of 60X coverage (3 million reads) per 
sample.  
 
2.1.21  Compound libraries 
The Pathogen Box® (http://www.pathogenbox.org/), modelled after the Malaria Box 
[72], is an open source library comprising of 400 diverse open source compounds targeting 
neglected tropical diseases. The Malaria Box was an open source library (until December 
2015) which comprised of 400 diverse compounds with antimalarial activity. In addition, 
the three drug candidates (the phosphatidylinositol-4-OH kinase (PI(4)K) inhibitor KDU691 
[66], the imidazolopiperazines GNF179 [42] and the spiroindolone KAF246 [41]) were 
included as additional controls. The selected 80 compounds in Figure 3.13 were obtained 
from MMV as a blinded compound screen in P. cynomolgi Berok K4 continuous culture to 
study the effects of serum in drug susceptibility. 
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2.1.22  Compound plate preparation  
Test compounds were prepared by serially diluting a 10 mM compound stock three-
fold with DMSO for 10 concentration points in the master compound plate. 100% DMSO 
was used as the negative control and 10 mM mefloquine was used as the positive control.  
A thousand-fold dilution (either 100 nL or 50 nL) of compound from master plate were 
spotted onto a 96-well or 384---well assay plate respectively using either the Mosquito® 
nanoliter dispenser (Cambridge, UK) or the Echo 550 liquid dispenser (Labcyte, U.S.A). 
The plates were then sealed with a removable foil seal using PlateLoc Thermal Microplate 
Sealer (Agilent) until use.  
 
2.1.23 Compound testing with P. cynomolgi Berok K4 using SYBR green I 
proliferation assay (collaboration with NITD) 
There are various high-throughput screens based on cultured P. falciparum [43, 63-
65, 69, 70] or on the hepatic stages of the rodent parasites P. berghei or P. yoelii [42, 70], 
described. In this study, we adapted the SYBR green I proliferation assay as described 
previously [69]. Briefly, 50 µL of the P. cynomolgi Berok K4 continuous culture was 
dispensed manually into the 384-well plate at both final parasitemia of 0.5% (for dose 
response assay) or 1% (for single point assay) and the haematocrit adjusted to 2.5%. The 
384-well assay plates were incubated at 37°C for 72 h in 5% CO2, 5% O2 and 90% N2. After 
a 72 h incubation, 10 µL of lysis buffer, consisting of 5 mM EDTA, 20 mM Tris-HCI pH 
7.5, 1.6% Triton X-100 and 0.16% Saponin were added to each well and the plate was 
incubated in the dark for 24 h at room temperature. The plate was read for fluorescence 
using BioTek Synergy™ 4 hybrid microplate reader (Vermont, USA) using a bottom read 
mode at excitation wavelength of 485 nm and emission wavelength of 528 nm. 
 
2.1.24 Schizont maturation assay with P. cynomolgi Berok K4 using flow cytometry 
analysis  
The schizont maturation assay for P. vivax was carried-out as previously described 
[19, 223]; where parasite development was assessed by flow cytometry [220]. 200 L of 
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tightly synchronised ring stage culture of P. cynomolgi Berok K4 was dispensed manually 
in the 96-well compound plate at a final parasitemia of 0.5% and haematocrit adjusted to 
2%. The assay plates were incubated at 37°C for around 44 h in 5% CO2, 5% O2 and 90% 
N2 until mid-late schizonts stage (> 5 merozoites) was observed in the drug free control 
wells via Giemsa staining. Each well was well mixed and 20 µL was harvested into a small 
curved-bottom tube (Micronic) before 0.5 L of 1 mg/mL dihydroethidium and 1 L of 
800uM of Hoechst 33342 was added and made up to 100 L with PBS. The tubes were 
incubated in the dark at room temperature for 20 min. After incubation, 400 L of cold PBS 
was added. 100,000 events were acquired with an Accuri C6 (BD Biosciences, US). The 
data were analysed using FlowJo software (Tree Star Inc.). 
 
2.1.25 Transmission study from P. cynomolgi Berok K4 continuous culture 
(collaboration with Biomedical Primate Research Center (BPRC)) 
Monkey infections and mosquito feedings were performed as previously described 
[93]. Briefly, cryopreserved in vitro adapted P. cynomolgi Berok K4 parasites were thawed 
as described above and one million parasites were used to infect one M. mulatta monkey via 
intravenous injection, while the monkey was under ketamine sedation. Parasitemia was 
monitored over time through Giemsa-stained thin smears. Female Anopheles stephensi 
mosquitoes were fed with infected monkey blood using a glass feeder system on days 12 
and 13 post infection, after which the monkey was cured from blood stage parasites with 
chloroquine (3 daily intramuscular injections 7.5 mg/kg). Oocysts were counted in at least 
10 mosquitoes at day 7 after the infected blood meal. The remaining mosquitoes were given 
a second uninfected blood meal to promote sporozoite invasion of the salivary glands.  
 
2.1.26 Sporozoites from P. cynomolgi Berok K4 strain (collaboration with BPRC) 
 As previously described [93], sporozoites were isolated from salivary glands of 
infected Anopheles stephensi mosquitoes eighteen days post infected blood meal. Briefly, 
Anopheles stephensi mosquitoes were fed on P. cynomolgi Berok K4 infected M. mulatta 
blood. Formation of oocysts was first determined in the infected mosquitoes a week after 
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the infected blood meal and sporozoites were subsequently isolated on the day of infection 
of the hepatocytes.  
 
2.1.27 Infectivity of sporozoites derived from P. cynomolgi Berok K4 continuous 
culture in hepatocyte monolayer (collaboration with BPRC) 
M. mulatta hepatocytes from different donors were isolated as previously described 
[93] and plated onto collagen coated 384-well plates at a density of 28,000 hepatocytes per 
well in William’s B medium as previously described [93]. Two days later, 20,000 
sporozoites were added to each well. Regular medium refreshments were performed, and 
the infected hepatocytes were fixed in 3.7% paraformaldehyde (PFA) after six days post 
infection. Parasites were immunostained with anti- P. cynomolgi heat shock protein 70 
(PcHsp70) antibodies and goat-anti-rabbit Alexa568 red secondary antibodies (Invitrogen 
A11011), while the nuclei were stained with DAPI before they were visualised using the 
Operetta high content screening automated microscope. Image analysis was done using the 
analysis algorithm as designed in previous study [93] with a minor adaptation for the change 
in fluorescent label of the secondary antibody. 
 
2.1.28 Statistical analysis 
The non-parametric data (all data sets failed the D'Agostino & Pearson normality 
test) presented in Figure 3.8(b, d, f and h) and Figure 3.15(d) was analysed using the Mann-
Whitney U-Test with the significance level set at P < 0.05. The parametric data presented in 
Figure 3.15(c and d) were analysed using the Welch’s t-test with the significance level set 
at P < 0.05. The histograms represent means and the error bars the standard deviation (SD). 
The histograms and lines on box plots and scatter plots represent medians and the error bars 
the interquartile range (ICQ). All analyses were carried out using GraphPad Prism™ 7 
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2.2.1  Ethical committees and animal welfare  
Macaca fascicularis (cynomolgous monkeys) were maintained at the Novartis 
Laboratory Animal Services, New Jersey, U.S.A., (Novartis-LAS) and SingHealth, 
Singapore. M. mulatta (rhesus monkeys) were maintained at the Armed Forces Research 
Institute of Medical Sciences, Bangkok, Thailand (AFRIMS). All three institutions were 
audited and approved by the Novartis Animal Welfare Compliance. All animals were housed 
in accordance with the Guide for the Care and Use of Laboratory Animals and the 
Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
Standards. All studies were approved by the Novartis Ethical Review Council and Novartis 
Institutional Animal Care and Use Committees (IACUC), protocol Number 100280 
Committees (IACUC protocol reference number 100280), prior to study initiation. 
Additionally, studies at AFRIMS were approved by the AFRIMS’ IACUC (protocol 
reference number PN13-06) and studies at SingHealth were approved by the SingHealth 
IACUC (protocol reference number 2015/SHS/1024).  
 
2.2.2  Scanning electron microscopy (SEM) of 3D Cellusponge  
Dry sponge discs (approx. 5 mm in diameter and 1 mm in height) were sputter coated 
with platinum for 60−90 s and the top view of the sponges was captured using a JSM-7400F 
Field Emission Scanning Electron Microscope at 5 kV.  
 
2.2.3  Confocal microscopy of 3D Cellusponge  
The porous structure of hydrated sponges was visualized by confocal microscopy as 
described previously [224]. Briefly, dry sponges were re-hydrated in PBS overnight at RT. 
The hydrated sponge was then immersed in 500 µL of propidium iodide (PI) (1 mg/mL in 
PBS) overnight. The sponge was washed 5 times with PBS to remove excess PI before 





2.2.4  Young’s modulus measurement of 3D Cellusponge  
Young’s modulus (E) was measured by an Instron Model 5848 Bench Top 
Microtester equipped with an Instron 2530-437 Static Load Cell. Dry sponges were re-
hydrated in PBS overnight. The hydrated sponges were compressed to 40% strain at 1 
mm/min at RT. Young’s modulus is equal to the slope of the linear region on the stress-
strain curve.   
 
2.2.5  Human and simian hepatocytes culture 
Cryopreserved human hepatocytes (Lot 358) were purchased from BD Biosciences 
while simian hepatocytes were either purchased from Invitrogen (CY380 and CY364) or 
isolated and cryopreserved in-house. Briefly, the cryopreserved hepatocytes were rapidly 
thawed in 39C water bath before the contents were transferred to pre-warmed recovery 
medium (Life technologies, CM7000). Next, they were pelleted and gently resuspended in 
pre-warmed 36% Percoll before centrifugation. The dead or unhealthy cells in the 
supernatant was discarded and the hepatocyte pellet was resuspended in plating medium and 
enumerated. Spheroid cultured hepatocytes were maintained in William’s E media 
supplemented with 1 mg/mL bovine serum albumin (BSA), 1X insulin-transferrin -
selenium, 50 ng/mL linoleic acid, 50 nM dexamethasone and 100 U/mL of penicillin 
/streptomycin. For infection of human and simian hepatocytes with P. vivax and P. 
cynomolgi sporozoites respectively and also for the maintenance of the respective 
hepatocytes in monolayer, William’s E medium supplemented with 2 mM L-glutamine (Cat. 
No. 2500-024, Life Technologies), 10% Hyclone FetalClone II Serum (Cat. No. 
SH30066.03, Hyclone), 5 µg/ml human insulin (Cat. No. I3536, Sigma), 2X penicillin/ 
streptomycin (Cat. No. 15140-122, Life Technologies) and 0.05 µM hydrocortisone (Sigma, 
H0888) was used. 
 
2.2.6  Urea synthesis  
49 
 
Supernatant was collected from cells cultured in both the cynomolgous hepatocytes 
cultured in monolayer and in spheroids. Urea synthesis was measured using a Urea Nitrogen 
kit (Cat. No. 0580, 250, StanBio). 
 
2.2.7  Fluorescein diacetate (FDA) staining  
The spheroid cultured human hepatocytes were incubated with 1.5 mg/ml of 
fluorescein di-acetate (Cat. No. F1303, Thermo Scientific) for 20 minutes before they were 
washed 5 times with PBS before imaging with confocal microscopy at 60X with an oil lens.  
 
2.2.8  Real-time PCR analysis for hepatocyte specific genes (collaboration with NUS) 
RNA was extracted from both monolayer cultured hepatocytes and spheroid-
cultured hepatocytes using RNeasy Mini Kit (Cat. No. 4104, Qiagen). Total RNA 
concentration was quantified by Nanodrop (Thermo Scientific), and 1 μg of RNA was 
converted to cDNA by high capacity RNA-to-cDNA kit (Cat. No. 4387406, Applied 
Biosystems). Primers were designed using Primer 3, and real-time PCR was performed by 
using SYBR Green fast master mix in an ABI 7500 Fast Real-Time PCR system (Applied 
Biosystems). Gene expression was plotted as a Log2 transcript over GAPDH. 
 
2.2.9  Sporozoites production and isolation from P. cynomolgi bastianellii (B) strain  
P. cynomolgi bastianellii (B strain) sporozoites were obtained by dissection of the 
salivary glands of infected Anopheles dirus mosquitoes obtained from the insectary in 
Armed Forces Research Institute of Medical Sciences (AFRIMS, Bangkok, Thailand).  
 
2.2.10 Infection of P. cynomolgi sporozoites with pre-formed 3D simian hepatic 
spheroids  
Simian hepatocytes were seeded at a density of 0.1 million cells per 6 mm 3D 
Cellusponge in a 48-well plate. After 45 minutes of incubation in a 37 ºC / 5% CO2 incubator, 
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280 L of additional medium was added to each well. Medium was refreshed every alternate 
day. Four days post seeding of 3D Cellusponge, P. cynomolgi sporozoites were added to the 
spheroid-cultured simian hepatocytes at various MoI (0.7, 2 and 4) in William’s E medium 
containing 10% serum.  After infection in 37 ºC/ 5% CO2 for 3 hours, the spheroids were 
washed 3 times and fresh maintenance medium was added. The infected spheroids were 
maintained in William’s E without serum with medium refreshment every alternate day 
before they were fixed with 3.7% PFA at respective end points to detect for liver-stage 
parasites using immunostaining.  
 
2.2.11 Infection of P. cynomolgi sporozoites with suspension simian hepatocytes prior 
to spheroid formation 
Simian hepatocytes and P. cynomolgi sporozoites (MoI: 2) were added to low 
attachment plate and co-incubated for 3 hours with shaking at 100 rpm in a 37 ºC / 5% CO2 
incubator with built-in shaker to facilitate sporozoites infection of the hepatocytes. The 
infected hepatocytes in suspension were then collected, washed extensively with PBS to 
remove the excess un-invaded P. cynomolgi sporozoites and seeded at a density of 0.1 
million cells per 6 mm 3D Cellusponge and maintained as described above.  
 
 2.2.12 Dissociation and plating of P. cynomolgi infected spheroids (collaboration with 
NUS) 
Uninfected and infected spheroids were harvested from the 3D Cellusponge, 
dissociated enzymatically using TrypLeTM (Cat. No. 12604013, Thermo Scientific) and 
plated on collagen coated 96-well plates overnight in 37 ºC / 5% CO2 incubator. Samples 
were then fixed with 3.7% PFA before they were immunostained and imaged using confocal 
microscopy. 
 
2.2.13  Drug treatment of P. cynomolgi and P. vivax exo-erythrocytic stages in 
spheroid-cultured hepatocytes  
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At selected time points post infection with P. cynomolgi and P. vivax sporozoites, 
the infected spheroid-cultured hepatocytes were incubated with medium containing 0.1% 
DMSO, 500 nM primaquine biphosphate (Cat. No. 156507, Sigma-Aldrich), 200 nM 
atovaquone (Cat. No. 1044651, Sigma-Aldrich) and 2 M of Novartis compound (KDU691) 
respectively.  
 
2.2.14  Complete maturation of P. cynomolgi liver-stages and blood stage transition in 
spheroid-cultured hepatocytes 
Naïve M. fascicularis red blood cells were added to P. cynomolgi infected spheroid-
cultured hepatocytes at 0.1% hematocrit on day 7, 10 and 14-post infection. Every day for 
five days, fresh red blood cells were added and samples of the red blood cells from the 
previous day’s culture were transferred to a separate well and cultured for another 48 hours 
before they were harvested. Thin blood smears were prepared, stained with 10% Giemsa for 
30 minutes and examined for asexual stage parasites.  
 
2.2.15  P. vivax sporozoites production and isolation 
For P. vivax mosquito infections from infected patients, isolates of P. vivax were 
collected from symptomatic patients with their informed consent at the Shoklo Malaria 
Research Unit (SMRU) in Tak province, Mae Sod Thailand. Briefly, Anopheles dirus and 
Anopheles cracens mosquitoes were fed on freshly collected blood samples from a P. vivax 
infected patient. Formation of oocysts was first determined in the respective infected 
mosquitoes and P. vivax sporozoites were isolated on the day of infection of the hepatocytes. 
 
2.2.16  Infection with P. vivax sporozoites of suspension human hepatocytes prior to 
spheroid formation 
Human hepatocytes and P. vivax sporozoites (MoI: 2) were added to a low 
attachment plate and co-incubated for three hours with shaking at 100 rpm in a 37ºC / 5% 
CO2 incubator with built-in shaker to facilitate sporozoites infection of the hepatocytes. The 
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infected hepatocytes in suspension were then collected, washed extensively with PBS to 
remove excess un-invaded P. vivax sporozoites and seeded at a density of 0.1 million cells 
per 6 mm 3D Cellusponge and maintained as described above. 
 
2.2.17  Immunostaining of P. cynomolgi and P. vivax infected and uninfected spheroid-
cultured hepatocytes  
Sporozoites infected and uninfected spheroids were fixed with 3.7% PFA for 15 
minutes at 37ºC followed by washing with PBS and blocking with 2% BSA /0.2% Triton-X 
100 for 2 hours. After which the spheroids were incubated overnight at 4ºC with either mouse 
anti-human CD-81 Clone JS-81 (Cat. No. 555675 BD Pharmingen), rabbit anti-MRP2 (Cat. 
No. M8316, Sigma-Aldrich), mouse anti-CD147 (Cat. No. ABCA2022492, Serotec), rabbit 
anti-PcHsp70, mouse anti-PcUIS4 or mouse anti-PvUIS4. Secondary antibodies used were 
goat anti-rabbit 488 and goat anti-mouse 555 (1:1000) respectively (Invitrogen). Nuclei stain 
was performed using mounting medium containing DAPI stain (Vecta Shield). All samples 
were blinded before it was sent for imaging and analysis. Images were captured using 
Olympus Fluoview FV1000 or Zeiss LSM 710 with a 60X water lens. Images were analysed 
using IMARIS (Bitplane scientific solutions, United Kingdom) and images assembled using 
Adobe illustrator CS2. 
 
2.2.18  Image analysis of P. cynomolgi and P. vivax infected spheroid-cultured 
hepatocytes (collaboration with NUS) 
The images of P. cynomolgi and P. vivax infection in 3D spheroid-cultured 
hepatocytes were pre-processed using the Fiji (Fiji ImageJ2) processing plugins to 
demarcate the spheroid boundaries (either 3D transformation of DAPI channel or creation 
of a pseudo-channel using summation of the DAPI and the GFP channels). The Imaris 
images analysis software (Bitplane), was used to determine the (1) GFP intensity summation 
within spheroid and the (2) DAPI intensity summation within spheroid. The Cell Module of 
Imaris was used, wherein the spheroids were treated as cells and the nuclei were treated as 
vesicles. The results were filtered to exclude spheroids that are too small or composed of 
cells without nuclei.  
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2.2.19  Statistical analysis 
All data were tested for normality using the Shapiro-Wilk normality test. The 
comparison of urea production between 3D Cellusponge and collagen monolayer and the 
comparison of the different P. cynomolgi treatment models were performed using two-tailed 
t-test. Comparison on the rate of P. cynomolgi infections for two distinct methods of 






Recipes for  
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2.3.1 Continuous in vitro culture of Plasmodium cynomolgi Berok K4 erythrocytic 
stages 
 
P. cynomolgi base medium  
RPMI 1640 (Roswell Park Memorial Institute) supplemented with GlutaMAX (Cat. No. 
61870-036, Gibco) containing 30 mM HEPES (Cat. No.  H4034, Sigma-Aldrich), 0.2% 
(w/v) D-glucose (Cat. No. G7021, Sigma-Aldrich) and 200 M hypoxanthine (Cat. No. 
4010BC, Calbiochem). Base medium was filter-sterilized over 0.22 µm filter and stored in 
4ºC and used within 1 month. 
 
P. cynomolgi complete medium  
To prepare complete medium, either 20% (v/v) heat inactivated M. fascicularis serum or 
20% (v/v) heat inactivated fetal bovine serum (Cat. No. 16000-036, Lot no. 1891471, Gibco) 
was added directly to sterile P. cynomolgi base medium. Complete medium was stored 4ºC 
and used within 2 weeks. 
 
M. fascicularis naïve blood washing medium 
30 mM HEPES (Cat. No.  H4034, Sigma-Aldrich) was added to RPMI 1640 (Roswell Park 
Memorial Institute) supplemented with GlutaMAX (Cat. No. 61870-036, Gibco). Wash 
medium was filter-sterilized over 0.22 µm filter and stored 4ºC and used within 1 month. 
 
10% Giemsa working solution  
Add 9 volumes of phosphate buffer (pH 7.2) to 1 volume of Giemsa (Cat. No. 352603R, 




5% (w/v) sorbitol 
5g of sorbitol (Cat. No. S1876, Sigma-Aldrich) was dissolved in 100 mL of distilled water 
and sterilized by filtration through a 0.22 m filter. Store in 4ºC until use.  
 
12% (w/v) NaCl and 1.6% (w/v) NaCl 
To prepare 12% (w/v) NaCl and 1.6% (w/v) NaCl solution, 12g and 1.6g of NaCl (Cat. No. 
S9888, Sigma-Alrich) was dissolved in 100 mL of distilled water respectively and sterilized 
by filtration through a 0.22 m filter. Store in 4ºC until use. 
 
2.3.2 3D hepatic spheroids to study P. cynomolgi exo-erythrocytic stages 
 
Medium for sporozoites-hepatocytes infection and for the maintenance of monolayer 
cultured hepatocytes 
William’s E (Cat. No. 12551-032, Life Technologies) medium supplemented with 2 mM L-
glutamine (Cat. No. 2500-024, Life Technologies), 10% Hyclone FetalClone II Serum (Cat. 
No. SH30066.03, Hyclone), 5 µg/ml human insulin (Cat. No. I3536, Sigma-Aldrich), 2X 
Penicillin/ Streptomycin (Cat. No. 15140-122, Life Technologies) and 0.05 µM 
hydrocortisone (Cat. No. H0888, Sigma-Aldrich) was prepared and sterilized by filtration 
through a 0.22 m filter. The medium was stored in 4ºC and used within 1 month. 
 
Maintenance medium for spheroid cultured hepatocytes 
William’s E medium (Cat. No. 12551-032, Life Technologies) supplemented with 1 mg/mL 
BSA (Cat. No. A2153, Sigma-Aldrich), 1X Insulin Transferrin and Selenium (Cat. No. 
51300044, Life Technologies), 50 ng/mL linoleic acid (Cat. No. L1012, Life Technologies), 
50 nM dexamethasone (Cat. No. D4901, Sigma-Aldrich) and 100 U/mL of Penicillin 
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/Streptomycin (Cat. No. 15140-122, Life Technologies) was prepared and sterilized by 
filtration through a 0.22 m filter. The medium was stored in 4ºC and used within 1 month. 
 
Plating medium for monolayer cultured hepatocytes 
William’s E medium without serum and phenol red (Cat. No. A1217601, Life Technologies) 
was supplemented with thawing/ plating supplement pack (Cat. No. CM3000, Life 
Technologies,) and sterilized by filtration through a 0.22 m filter. The medium was stored 
in 4ºC and used within 1 month. 
 
36% (v/v) Percoll 
To prepare 100ml of 36% (v/v) Percoll, 36 mL of Percoll (Cat. No. 170891-01, GE 
Healthcare,) and 4 mL of 10X PBS (Cat. No. 70011-044, Life Technologies) was added to 
60 mL of William’s E medium (Cat. No. 12551-032, Life Technologies) before sterilization 
through a 0.22 m filter. The solution was stored in 4ºC and used within 1 month. 
 
Sporozoites dissection medium 
Schneider insect medium (Cat. No. S9895, Sigma-Aldrich) supplemented with 4X 
Penicillin/ Streptomycin (Cat. No. 15140-12200, Life Technologies) and 0.5 g/ mL 
amphotericin B (Cat. No. A2942, Sigma-Aldrich) before sterilization through a 0.22 m 
filter. The medium was prepared on the day of usage and used within the day.  
 
3.7% (v/v) paraformaldehyde 
To prepare 50 mL of 3.7% (v/v) paraformaldehyde, 11.6 mL of 16% paraformaldehyde (Cat. 







CHAPTER 3 - RESULTS 
 
Development of the 
continuous in vitro culture 
of P. cynomolgi Berok K4 
erythrocytic stages  
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3.1  Propagation of P. cynomolgi strains 
Three P. cynomolgi lines were available to us: Berok strain [212] cryopreserved in 
1998 from Aotus trivirgatus, B strain (P. cynomolgi bastianelli) [162], and M (P. cynomolgi 
mulligan) strain [140]. Separate Macaca fascicularis monkeys were successfully infected 
with one or other of these lines and blood samples were collected to initiate cultures. We 
conducted preliminary experiments using the Berok strain, to test various culture conditions 
and materials in short-term cultures initiated from cryopreserved stocks prepared from 
infected monkey blood (Figure 3.1). This allowed us to define an optimal working protocol 
that was then tested on Berok strain parasites from different animals, and on B and M strain 
parasites freshly collected from infected macaques. The robust continuous culture of P. 
cynomolgi Berok K4 parasites were subsequently used for further work involving molecular, 






3.2  Robust multiplication of the continuous culture of P. cynomolgi Berok K4 
strain 
Blood was collected when the parasites were predominantly mature (late 
trophozoites and schizonts) and depleted of leukocytes before enrichment of the mature 
parasites on a Percoll gradient. In vitro cultures were initiated at parasitemia > 1% (50,000 
parasites/ µL) and monitored daily by microscopic examination of Giemsa-stained smears. 
In repeated independent experiments the parasitemia of the B and M strain cultures declined 
to become undetectable within a few days (Figure 3.2a). The parasitemia of the Berok strain 
parasites obtained from one of the monkeys (K4), but not the others, increased such that 
regular dilution of this culture became necessary within two days post-seeding in contrast 
from the P. cynomolgi bastianelli strain (Figure 3.2b). For these Berok K4 parasites, ring 






Figure 3.2. In vitro culture of P. cynomolgi (Berok K4 strain, bastianelli (B) and Mulligan 
(M) strain) erythrocytic stages initiated from infected monkeys. (a) Pilot ex vivo culture of 
P. cynomolgi Berok, B and M strain. (b) Multiplication of the P. cynomolgi Berok K4 strain 
necessitated regular dilution of this strain which was in contrast to the P. cynomolgi B 
strain.    
























3.3  Biological and morphological characteristics of in vitro cultured Berok K4 line 
A culture was initiated, using sorbitol synchronised and MACS columns-
concentrated mature blood stage parasites, and then sampled at two hourly intervals for 48 
h (Figure 3.3). The morphology of the parasites was indistinguishable from that observed 
or previously described from infected animals. Eight to sixteen merozoites were observed 
in fully mature schizonts around 46-48 h. Gametocytes were observed in vitro, albeit in 
low numbers, which probably accounts for the low level of transmission of the parasite 
from continuous culture to mosquitoes. It was not clear at this point whether these 
laboratory-and culture-adapted parasites had thereby lost their infectiousness to their insect 
hosts, as had been previously observed for some culture-adapted parasites, such as the P. 
knowlesi H strain that lost the capacity to produce gametocytes [225]
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Figure 3.3. Tertian cycle of the P. cynomolgi Berok K4 continuous culture. Mature schizonts of culture adapted P. cynomolgi Berok 
K4 were enriched and allowed to re-invade fresh red blood cells that were then monitored every two hours to document the complete 
asexual erythrocytic cycle in vitro.
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3.4  Culture characteristics of the heterogeneous P. cynomolgi Berok K4 line 
The initial Berok K4 line culture (multiplication rate ranging from 2 to 4-fold over 
more than 5 cycles) was used to constitute a working cryopreserved stock. Successful 
propagation of the line was maintained for up to 180 days in cultures initiated with thawed 
parasites. Culture conditions were further refined, with robust growth best observed under 
reduced oxygen environment (5% CO2, 5% O2 and 90% N2) to reach parasitemia beyond 
10% (i.e. 500,000 parasites/ L) after sub-culturing (Figure 3.4a). Growth rates were 
unaffected when different culture vessels were used (24-well plate, 6-well plate, T25 or 
T75 flasks). The P. cynomolgi Berok K4 parasites retained their distinct morphological 
features throughout the 30 days of in vitro culture. The robustness of the P. cynomolgi in 
vitro-grown Berok K4 stabilates was independently validated by successful in vitro 
cultivation in six additional laboratories (the National University of Singapore, the 
University of Otago in New Zealand, the University of Malaya in Malaysia, the Shoklo 
Malaria Research Unit in Thailand, the Université Pierre et Marie Curie in France and the 
Novartis Institute of Infectious Diseases in United States of America).  
The parasitemia of the Berok strain parasites obtained from only one of the 
monkeys (K4), but not the others, increased at such a high rate that such that regular dilution 
of this culture became necessary within two days post-seeding (Figure 3.4a). In contrast 
from the P. cynomolgi B and M strains never showed substantial increases in parasitemia. 
For these Berok K4 parasites, ring stages were regularly observed as were a few 
gametocytes from day 6 post thaw. Like the laboratory adapted strains of P. falciparum, 
the P. cynomolgi Berok K4 stain retains its morphological characteristics through the 
duration of continuous culture in vitro (Figure 3.4b).  
One crucial aspect to ensure the successful cultivation of P. cynomolgi Berok K4 in 
vitro is not to include any antibiotics in its culture medium. Unlike P. falciparum 
continuous culture where antibiotics are commonly added to prevent contamination, the 
addition of any antibiotics (e.g. gentamicin and penicillin-streptomycin) even at low 
concentrations caused the P. cynomolgi Berok K4 continuous culture to ultimately die off. 
In contrast, the culture which was grown in the absence of antibiotics grew robustly with 
regular sub-culturing required (Figure 3.4c). This phenomenon was consistently observed 




Figure 3.4. Robust continuous culture of P. cynomolgi Berok K4 (a) High amplification rate 
of the parasites over 30 days in continuous culture (b) Similar morphology of the ring, 
trophozoite and schizonts stages of the in vitro culture of P. cynomolgi Berok K4 strain over 
30 days in continuous culture (c) Effect of antibiotics on the continuous culture of P. 
cynomolgi Berok K4 (red arrows signify days when cultures were sub-cultured)















































3.5  Selection of homogeneous parasite populations (clones) from heterogeneous 
population of P. cynomolgi Berok K4 continuous culture 
3.5.1  Isolation of P. cynomolgi Berok K4 clones 
With the establishment of Berok K4 strain continuous culture, our next objective 
was to isolate single parasite clones from the heterogeneous parent culture by limiting 
dilution method. Obtaining single parasite clone facilitates the conduct of various 
techniques in malaria research such as genotyping [226], drug resistance testing [222], 
genetic manipulation [227]. Limiting dilution is a standard method for the in vitro cloning 
of P. falciparum, particularly after genetic manipulation [228]. The method entails the 
dilution of the heterogeneous parasite population with uninfected erythrocytes in 96-well 
plates at less than one infected erythrocyte per well. Conventionally, positive wells used to 
be determined after a few weeks of culture by microscopic determination of Giemsa 
smears. However, various methods have since facilitated this laborious effort through the 
detection of parasite DNA [220, 229], enzymatic activity [228] or secreted proteins [230]. 
In this study, we carried out limiting dilution and isolated 5 positive clones (K4-
A5, K4-B5, K4-G5, K4-A7 and K4-F10) from the parental Berok K4 strain on Day 55 post 
clonal dilution through FACS detection (Appendix B). The remaining wells in the clonal 
plate was monitored for another 3 weeks to prevent the possibility of discarding slow 
growing clones before the clonal plate was discarded. All of the isolated clones were 
amplified in vitro and cryopreserved except for clone K4-F10.  As anticipated, the 
respective clones demonstrated different rates of amplification in the well (Figure 3.5a and 
3.5b) where clones K4-A5, K4-B5, K4-G5 and K4-A7 were detected via FACS on day 45 
while clone K4-F10 was only detected in Day 55 of culture. With the clonal dilution 
method, clones derived from columns 6 to 11 (i.e. K4-A7 and K4-F10) in the clonal plate 
should technically arise from a single parasite in the well. Even though both clones were 
isolated on Day 55, only K4-A7 continued to show robust growth when isolated from the 
clonal plate while the growth of K4-F10 stagnated with no amplification observed via 
Giemsa smears.  
 Whole genomic sequencing using Oxford Nanopore and Illumina sequencing was 




Figure 3.5. Clonal isolation of homogenous populations of P. cynomolgi Berok K4 via 
dilution method. (a) Different growth rates of positive clones (b) Cumulative amplification 






































































3.5.2  Morphology and serum adaptation of P. cynomolgi K4-A7 clone 
Morphologically, P. cynomolgi Berok K4-A7 parasites grown in complete medium 
containing 20% M. fascicularis serum in continuous culture retains characteristic features 
(Figure 3.6) similar to its original heterogeneous population from P. cynomolgi Berok K4.  
The trophozoites (T1 to T8) from the K4-A7 clone has the distinct amoeboid cytoplasm 
which occupied half of the RBC. Like the original heterogeneous population, Schüffner’s 
stippling was also observed in both trophozoites (T1 to T8) and schizonts (S1 to S8) where 
eight to sixteen merozoites were commonly observed in the latter. Like the heterogeneous 
population from P. cynomolgi Berok K4, enlargement of the infected host cells were 
observed in the later stages of the parasites.  
To limit the use of naïve monkey blood in the continuous culture of the P. 
cynomolgi Berok K4-A7 clone, it was adapted to grow in complete medium containing 
20% fetal bovine serum (FBS). The morphology of the Berok K4-A7 clone grown in 
complete medium containing 20% FBS shared similar distinct features (Figure 3.7) to its 
counterpart grown in 20% M. fascicularis serum. Interestingly, enlargement of the infected 





Figure 3.6. Representative images of asexual erythrocytic stages of P. cynomolgi Berok 
K4-A7 clone grown in complete medium containing 20% M. fascicularis serum 
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Figure 3.7. Representative images of asexual erythrocytic stages of P. cynomolgi Berok 
K4-A7 clone grown in complete medium containing 20% fetal bovine serum 
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3.6  Phenotypic and genotypic characterization of heterogenous P. cynomolgi 
Berok K4 continuous culture 
3.6.1  Nanostructure and rheology of P. cynomolgi Berok K4-infected RBCs 
(collaboration with NUS and SIgN)  
P. cynomolgi Berok K4 dramatically alters the nanostructural and rheological 
properties of the iRBC in a manner similar to that observed for P. vivax. Caveolae (~90 
nm-diameter openings) appear on the surface of the infected RBCs. While these caveolae, 
that are generally associated with vesicle complexes, have the same dimensions as those 
noted in P. vivax, they are present in significantly lesser densities (Figure 3.8a-d), our data 
on caveolae agree with previous in-depth analyses conducted on P. cynomolgi Berok [231]. 
The P. cynomolgi Berok K4-infected RBC increases in size with maturation (rings ~5 µm 
and schizonts ~8 µm) with rosettes forming approximately 20 h post-invasion (Figure 3.8e 
and 3.8f), a timeline similar to that previously noted for P. vivax [221]. It is interesting that 
rosettes had not been observed in earlier studies on the B and M strains [232]. The P. 
cynomolgi Berok K4 rosettes formed highly stable adhesive bonds requiring around 400 
pN (piconewton) to affect a separation (Figure 3.8g and 3.8h), an adhesive force similar to 
that recorded for P. vivax  [233].  
As rosetting was only observed in the Berok K4 strain and not in the B or M strain 
of P. cynomolgi, we further evaluated the rate of rosetting across the different erythrocytic 
stages of Berok K4 (Figure 3.9a). Rosette was not found in the ring stages, which is a 
similar observation from P. falciparum and P. vivax [221]. Rosetting was noted at the early 
trophozoite stage, and the rosetting rate increased with the maturation of the parasites until 
it reached plateau at the late trophozoite stage. Interestingly, as the mature schizonts are 
ready for rupture and release (segmenter), the rosetting rate decreased, where most of the 







Figure 3.8. Phenotypic and rheological characterization of the heterogeneous Berok K4 
strain from in vitro culture. (a) P. cynomolgi Berok K4 infected RBCs exhibit caveolae 
structures that are similar to those in P. vivax infected RBCs (Scanning Electron 
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Microscopy, scale bars represent 1 µm and 100 nm for area shown at higher magnification 
in white box). (b) An atomic force microscope scan of trophozoite infected blood cells, 
revealed caveolae occurred at lower frequency when compared to P. vivax. (c,d) The 
median (+/- IQR) dimensions of these caveolae were similar. (e, f) Amnis flow imaging 
clearly shows that the mature erythrocytic stages P. cynomolgi Berok K4; readily formed 
rosettes with uninfected red blood cells, which are also a key feature P. vivax. (g, h) A dual 
micropipette aspiration method was used to demonstrate the rheological stability of the P. 
cynomolgi Berok K4 rosettes.  As observed in P. vivax, P. cynomolgi rosettes are tightly 
attached and the cells require around 400 pN (piconewton) to disrupt the adhesion. The 
non-parametric data in (b, d, f, h) was analysed using Mann-Whitney U-Test with the 




Figure 3.9. Rate of rosetting across different asexual erythrocytic stages of Berok K4 strain 
(a) Development of rosetting along the maturation of P. cynomolgi Berok K4 erythrocytic 
maturation. (b) a mature segmenter of P. cynomolgi Berok K4 
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3.6.2  Molecular characterization of in vitro cultured P. cynomolgi Berok K4 strain 
and clonal strain P. cynomolgi Berok K4-A7 
Genotyping of the reticulocyte binding protein (rbp) genes from the parasite lines 
used confirmed that parasites in the heterogeneous population of P. cynomolgi Berok K4 
and the clonal strain P. cynomolgi Berok K4-A7 were indeed derived from the original 
Berok stock (Figure 3.10). Copy number variations had been observed for rbp1b and rbp2a 
with the genetically related Berok and Gombak strains, and in accordance to previous 
studies [171, 172], rbp1b was found in the Berok strain only, rbp2a in the M and B strains 





K4: Heterogeneous population of P. cynomolgi Berok K4 
A7: Clonal strain of P. cynomolgi Berok K4-A7 
B: P. cynomolgi B strain 
(-): Negative control 
Figure 3.10. Genotyping of the reticulocyte binding protein (rbp) genes of the P. 
cynomolgi Berok K4, the clonal strain A7 and B strain 
  






CGATAATTTGACAGCGGCGG GCCCTATATCGGGTTCTGCC 875 
rbp2a B, M AATTGTTCAGCACACCAGAAGG ACAAACACCCAACCCCAAAATC 149 
rbp2b B, M TGGAAATAAACGCACTTTGGACG GGGGAGCCTGTTTTGGTGAG 668 
rpb2b 
Berok 
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3.6.3  Whole genomic sequencing of P. cynomolgi Berok K4-A7 clone (collaboration 
with SIgN) 
In order to enable future technologies or genomic studies to be carried out on P. 
cynomolgi Berok K4-A7, whole genomic sequencing was carried out using Oxford 
Nanopore and Illumina. This combination was used so that the long sequence reads derived 
from Oxford Nanopore can be complemented with the short sequence reads from Illumina.  
Sequence analysis from both methods requires a considerable amount of time and effort. 
However, preliminary results from Oxford Nanopore sequencing using Sanger/ Illumina 
1.9 encoding showed a 36% GC content of the genome with lengths of read ranging from 
5 to 144, 963bp (). This GC content is in agreement with previous study where the GC 
content in P. cynomolgi is around 40.5% [172]. Currently (as of date of submission of 
thesis), the complete analysis of the sequencing data generated from both Oxford Nanopore 






3.7  Plasmodium cynomolgi Berok K4 in vitro culture as a platform for drug 
susceptibility testing  
3.7.1  Drug susceptibility testing in P. cynomolgi Berok K4 asexual erythrocytic 
stages using a high-throughput screening assay (collaboration with NITD)  
We opted to validate the SYBR green I proliferation assay [69, 234], used routinely 
for anti-P. falciparum drug screening, for use with the P. cynomolgi Berok K4 line to 
establish dose response and single point screens based on 96 and 384 well-plate assay 
formats (Figure 3.11a-c). Using the BioTek Synergy™ 4 hybrid microplate reader, the 
range of the 72 h fluorescent read-out in the SYBR green I proliferation assay showed a 
linear correlation with parasitaemia in the range of 0.3-2%.  
A SYBR green I dose response assay was performed in a 384-well plate format 
using a set of reference compounds (Figure 3.11a) and selected compounds (Figure 3.11b) 
from the Malaria Box. Culture medium was supplemented with 20% macaque serum for 
the Berok K4 line, whereas 0.5% Albumax was used for P. falciparum. The reference 
compounds included the licensed antimalarials chloroquine, lumefantrine, pyrimethamine, 
artemisinin, atovaquone, and artesunate, as well as three drug candidates: the 
phosphatidylinositol-4-OH kinase (PI(4)K) inhibitor KDU691 [66], the 
imidazolopiperazines GNF179 [42] and the spiroindolone KAF246 [41] (GNF179 and 
KAF246 are analogues to KAF156 and KAE609 currently in phase 2b clinical trials [235]) 
. The IC50 values measured for both species were broadly concordant, though P. cynomolgi 
proved more sensitive to artesunate, artemisinin and atovaquone (Figure 3.11a). The assay 
was also conducted for 38 in-house synthesized compounds from the Malaria Box [72] 
(Figure 3.11b) and identified some that had differential inhibitory activity against the two 
parasites species. For example, MMV000563, MMV007839 and MMV008294 were highly 
active against P. falciparum but not P. cynomolgi. 
In order to evaluate whether the type of culture supplement (serum or Albumax) 
influences inhibitory activity, the Pathogen Box® chemical library (Medicines for Malaria 
Venture, Switzerland) was screened in a 384-well format as a single point assay at 10 µM 
(Figure 3.11c) using P. cynomolgi (20% serum) or P. falciparum (20 % human serum or 
0.5% Albumax). The Pathogen Box® comprises 400 compounds, of which 125 are 
antimalarial tool-compounds, while the rest include 26 reference compounds active against 
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tuberculosis (n= 116), kinetoplastids (n= 70), helminths (n= 32), cryptosporidiosis (n= 11), 
toxoplasmosis (n= 15) and dengue (n= 5) (http://www.pathogenbox.org/). Assay data for 
P. cynomolgi in 20% macaque serum (Column A) proved to be highly comparable to that 
obtained for P. falciparum in 20% human serum (Column B), but both assays differed 
significantly from the P. falciparum assay performed in 0.5% Albumax (Column C). This 
observation was not surprising given the high protein content of 20% serum-supplemented 
media with the likely consequent effect on protein binding. As above, the rate of inhibition 
of nine anti-malarial compounds (MMV676380, MMV023388, MMV026550, 
MMV007625, MMV023949, MMV007638, MMV676442, MMV006833, MMV020289) 
were significantly different for both parasite species in the presence of 20% serum (Figure 
3.11 c). Overall, the SYBR green I proliferation assay demonstrated robust reproducibility, 













A: P. cynomolgi in 20% Mf serum
B: P. falciparum in 20% human serum
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Figure 3.11. Drug susceptibility testing using P. cynomolgi Berok K4 in vitro culture. (a) 
Correlation of P. cynomolgi Berok K4 and P. falciparum IC50 values of common 
antimalarial reference compounds in a SYBR green I proliferation assay. The potency of 
the compounds was comparable between the two species except for artemisinin, 
atovaquone and artesunate which were more potent in P. cynomolgi as compared to P. 
falciparum. A X=Y line indicates equal inhibition towards compound. (b) Heat map 
showing IC50 (M) of representative set of compounds from the Malaria Box. Majority of 
the compounds showed activity against both P. falciparum and P. cynomolgi except for 6 
compounds - MMV000563, MMV006250, MMV007839, MMV008127, MMV008270  
and MMV008294 which displayed an IC50 >10 µM for P. cynomolgi, and <5 µM for P. 
falciparum. (c) Heat map showing percentage of inhibition of compounds from the 
Pathogen Box® in P. cynomolgi Berok K4 and P. falciparum in different serums and 
concentrations. Nine compounds (MMV676380, MMV023388, MMV026550, 
MMV007625, MMV023949, MMV007638, MMV676442, MMV006833, MMV020289) 
from the anti-malarial subset of the Pathogen Box® showed more than 4-fold difference in 




3.7.2  Evaluating the effect of serum on P. cynomolgi Berok K4 based high-
throughput screening assay for asexual erythrocytic stages 
From the request from Medicines for Malaria Venture, we next evaluated the effect 
of serum used in drug screening for malaria asexual erythrocytic stages. Using the 
established P. cynomolgi Berok K4 line-based high-throughput screening assay for asexual 
erythrocytic stages, we compared the serum conditions (0.5% albumax) routinely used in 
the P. falciparum SYBR green I proliferation assay [69, 234]  with the more physiologically 
relevant serum condition (20% M. fascicularis serum) for 80 blinded compounds. As 
expected, the P. cynomolgi Berok K4 high-throughput screening assay was reliable in 
predicting the IC50 values of the positive and negative controls of compounds which were 
included in the screen. For instance, the screen showed inactivity for negative controls such 
as primaquine, riboflavin and deoxyDHA (IC50 > 10 M) while showing high potency in 
positive controls such as artemether, artemisinin and atovaquone (in single-digit nM range). 
10% of the compounds demonstrated 5-fold difference in potency between the 2 serum 
conditions (highlighted as red dots in Figure 3.12). The compounds which were more 
potent in 20% serum were hydrocxychloroquine, sulfamethoxazole, UCT944 and DB-75 
while compounds which were less potent in 20% serum were DSM265, KAF-156, 21A092 
and cladosporin. The compounds which showed decreased potency in 20% serum is of 
particular importance as they tallied with P. vivax clinical outcomes. For instance, the 
dihydroororate dehydrogenase inhibitor (DSM265), a phase II clinical candidate which 
blocks the pyrimidine biosynthesis of the parasite, demonstrated 10-fold less potency in 
20% serum condition (~60 nM) compared with 0.5% albumax (~6 nM). This result 
corresponded with clinical outcome as it was more active on P. falciparum field isolates 
than P. vivax field isolates [44, 236]. While its improved sister compound (DSM421) 
demonstrated equal potency in both serum conditions (~60 nM) in the P. cynomolgi Berok 
K4 line-based high-throughput screening assay which also tallied with the clinical 
outcomes in both P. falciparum and P. vivax field isolates [236]. Such results further 
validated the robustness and potential of the use of P. cynomolgi Berok K4 line-based high-






Figure 3.12. Correlation of IC50 values of 80 selected MMV compounds in P. cynomolgi 
Berok K4 in vitro culture via SyBr green I proliferation assay in different serum conditions 
(20% M. fascicularis serum versus 0.5% albumax). Red dots signify compounds which 
showed at least 5-fold difference in the IC50 values between the two serum conditions.  
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3.7.3  Comparative schizont maturation assays using P. cynomolgi Berok K4 and P. 
vivax 
In vitro cultured P. cynomolgi is ultimately to be used as a surrogate for P. vivax in 
drug sensitivity assays. Therefore, we carried out the standard schizont maturation assay 
routinely used for the drug susceptibility determination of P. vivax with tightly 
synchronized Berok K4 ring stage cultures as well as several clinical P. vivax isolates. The 
Berok K4 parasites were seeded on plates containing serially diluted chloroquine, and 
parasite growth was assessed about 44 hours later by flow cytometry [220] (Figure 3.13a). 
In parallel, the SYBR Green I proliferation assay was carried out for the same drug using 
Berok K4. Each dot represents individual P. vivax clinical isolate and replicates for Berok 
K4 line respectively. The IC50 values for chloroquine were similar for Berok K4 in the 
schizont maturation assay (Figure 3.13b) and the SYBR Green I proliferation assay (Figure 
3.13c), and equally comparable to the IC50 values (~50 nM) obtained from the P. vivax 






Figure 3.13. Correlation of chloroquine IC50 values of P. cynomolgi Berok K4 continuous 
culture with P. vivax clinical isolates. (a) Flow cytometry dot plots (Hoechst/ Ethidium) of 
chloroquine treated P. cynomolgi Berok K4 continuous culture gated for schizonts 
population in replicates. (b) IC50 determination of chloroquine in P. cynomolgi Berok K4 
continuous culture using the schizont maturation assay. (c) IC50 determination of 
chloroquine in P. cynomolgi Berok K4 continuous culture using the SYBR green I 
proliferation assay. (d) IC50 of chloroquine in P. cynomolgi Berok K4 continuous culture 
and P. vivax clinical isolates using the schizont maturation assay. The median (+/- IQR) 
values for the IC50 of P. vivax clinical isolates and of P. cynomolgi Berok K4 continuous 
culture were similar. 
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3.8  Transmission study of P. cynomolgi Berok K4 continuous culture 
(collaboration with BPRC) 
In vitro cultured Berok K4 parasites were used successfully to infect a naive intact 
rhesus (M. mulatta) monkey, where asexual and sexual stages were observed 6 days post-
infection (dpi) and thereafter. Anopheles stephensi mosquitoes fed at 11 and 12 dpi (0.85% 
and 1.4% parasitaemia respectively) showed oocysts a week later (feed 11 dpi: in 40% of 
mosquitoes, average of 3.5 oocysts/mosquito; feed 12 dpi: in 90% of mosquitoes, average 
of 37.6 oocysts/mosquito). Eighteen days after feeding, lots of 100,000 sporozoites isolated 
from salivary glands of infected mosquitoes (feed 12 dpi: ca. 31,000 sporozoites per 
mosquito) were successfully used to infect two naïve M. mulatta monkeys and the course 
of infection was monitored by microscopy. Both monkeys became patent 11 dpi (Figure 
3.14a), and were later administered a 5-days chloroquine treatment to eliminate blood stage 
parasites in order to monitor for relapses as previously described [94]. Monkey 1 relapsed 
31 dpi and 52 dpi, after which radical cure was administered (chloroquine and primaquine), 
while the second monkey remained negative for the whole duration of follow-up (102 dpi). 
The time to patency was similar to that noted for P. cynomolgi M strain infections (using 
the same sporozoites inoculum and infection route), as was that for the first relapse (around 
day 27.5 ± 3.25 dpi in eight monkeys infected by the M strain [94]). Usually, monkeys 
infected with P. cynomolgi M strain relapse at least once, regardless of inoculation dose, 
which contrasts with the relapse episodes noted in only one of two rhesus monkeys 
inoculated with the P. cynomolgi Berok K4 sporozoites.  
Sporozoites were also used to infect in vitro-cultured M. mulatta primary 
hepatocytes as previously described [211], and six days later schizonts and uninucleate 
parasites (possibly hypnozoites) were detectable (Figure 3.14b). The average infectivity of 
the sporozoites derived from P. cynomolgi Berok K4 was lower, around 16 pre-erythrocytic 
(PE) forms per 10,000 inoculated sporozoites, than those derived from the P. cynomolgi M 
strain, around 23 PE forms per 10,000 inoculated sporozoites (Figure 3.14c). Enumeration 
of the two hepatic forms suggested that P. cynomolgi Berok K4 generated half the number 
of hypnozoites (around 30%) compared to the P. cynomolgi M strain (around 60%) (Figure 
3.14d). Further studies are required to ascertain whether the failure of one of the monkeys 
infected with the Berok K4 line to relapse reflects with the lower numbers of uninucleate 
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Figure 3.14.  Transmission study from P. cynomolgi Berok K4 continuous culture. (a) In 
vivo blood stage parasitemia in 2 rhesus monkeys infected with 100,000 P. cynomolgi 
Berok K4 sporozoites (because of the use of a log scale for parasitemia, negative smears 
are shown as 0.0001% parasitemia). Both monkeys became blood stage patent on day 11 
post-infection. Arrows indicate drug treatment (black arrows: 5-day chloroquine (CQ) 
treatment, red arrow: 7-day primaquine (PQ) treatment). Monkey 1 was bled for stocks on 
day 15 and relapsed (measured as thin smear positivity) on days 31 and 52 post-infection, 
after which it was treated with CQ and PQ. Monkey 2 was bled on day19 post-infection 
and did not relapse during the follow-up period of 102 days post-infection, after which it 
was treated with PQ. (b) In vitro infection of primary rhesus hepatocytes with P. cynomolgi 
Berok K4 sporozoites produced both hypnozoites (left panel) and developing liver stage 
schizonts (right panel). Cultures were fixed at day 6 post-infection and stained with anti-
PcHsp70 and a secondary antibody labelled with Alexa 568 fluorescent dye. Nuclei were 
stained with DAPI. An average of 16 PE forms per 10,000 inoculated P. cynomolgi Berok 
K4 sporozoites were observed. (c) The total pre-erythrocytic forms of in vitro infection rate 
of various primary rhesus hepatocytes with P. cynomolgi M strain sporozoites and P. 
cynomolgi Berok K4 strain sporozoites. (d) The percentage of hypnozoites observed in 
vitro using primary rhesus hepatocytes from different donors infected with P. cynomolgi 





CHAPTER 4 - RESULTS 
 
Establishment of a 3D 
hepatic spheroid model to 
study the exo-erythrocytic 
stages of Plasmodium 
cynomolgi 
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4.1  3D Cellusponge characterization  
Once the sporozoites derived from the continuous culture of the P. cynomolgi Berok 
K4 proved to be infectious, we next looked into the feasibility of developing a predictive 
radical cure model for drug screening of exo-erythrocytic stages of P. cynomolgi. The disc-
shaped 3D Cellusponge (Invitrocue) [100] (Figure 4.1a) was  chosen as previous studies 
have shown its robustness in the formation of spheroids derived from rodent hepatocytes  
and human hepatocytes which the latter spheroids were subsequently infected  with 
hepatitis C virus (HCV) [98]. Fabricated from inert hydroxypropyl cellulose, 3D 
Cellusponge exhibited an interconnected porous structure in the dry state as observed under 
SEM (Figure 4.1b). This porous structure was maintained after the scaffold was rehydrated 
as shown by bright-field microscopy (Figure 4.1c). To further verify the macroporosity in 
its hydrated state, the sponge was stained with propidium iodide (PI), which was absorbed 
unspecifically by the scaffold. Confocal image clearly showed that the hydrated PI-stained 
sponge contained pores from 50 to 200 µm in diameter (Figure 4.1c and 4.1d). Taken 
together, the results confirmed the macroporous structure of the sponge in both dry and 
hydrated states. Young’s modulus of the hydrated sponge was determined to be 25.4 ± 2.1 
kPa (n = 2).  
Spheroid formation in the 3D Cellusponge platform has been established for rodent 
and human hepatocytes but not for simian (M. fascicularis) hepatocytes [98, 100]. Herein, 
the feasibility of spheroid formation using simian hepatocytes was evaluated. Both 
uninfected simian hepatocytes (Figure 4.2a) and sporozoites pre-infected simian 
hepatocytes (Figure 4.2b) were evaluated for their ability to form spheroids in the 3D 
Cellusponge. Next, we evaluated adherent simian hepatocyte viability in standard 
monolayer culture seeded on collagen-coated plates [237] and subsequently on spheroids 
formed in the 3D Cellusponge platform . The ability of the spheroids formed from pre-
infected simian hepatocytes (Figure 4.2b) was further investigated for its ability to 
complete the parasites life cycle into the erythrocytic stages from the exo-erythrocytic 
stages (Figure 4c) and the potential use as a platform for liver stage drug screening (Figure 









Figure 4.1. Characterization of 3D Cellusponge. (a) Photograph of 3D Cellusponge. (b) 
SEM image of a dry Cellusponge. (c) Bright-field image of a hydrated Cellusponge in PBS. 







Figure 4.2. Schematic diagram showing the work flow of P. cynomolgi sporozoite 
infection.  (a) Spheroids formed using uninfected hepatocytes (b) Spheroids formed using 
sporozoites pre-infected hepatocytes and subsequent studies for (c) Reinfection in blood 































































































4.2  Maintenance of hepatocyte synthetic function in spheroid-cultured simian 
hepatocytes  
In both systems of using uninfected simian hepatocytes (Figure 4.2a) and 
sporozoites pre-infected simian hepatocytes (Figure 4.2b), compact spheroids of simian 
hepatocytes started forming from day four post seeding in the 3D Cellusponge platform. 
Conversely, hepatocyte detachment was noted from day four in the monolayer cultures 
(Figure 4.3a). After a week in culture, the hepatocytes in the monolayer culture 
dedifferentiated to a fibroblast like phenotype, while the spheroid-cultured hepatocytes 
formed in the 3D Cellusponge platform maintained their structural integrity for up to 60 
days (Figure 4.3a). Viability of the spheroids was assessed using calcein-AM/PI staining 
(calcein acetoxymethyl ester- propidium iodide) (Figure 4.3b). We then evaluated the urea 
production on adherent simian hepatocytes in monolayer culture as compared to spheroid-
cultured hepatocytes (Figure 4.3c). Urea production is used as a marker to determine 
hepatocyte functionality [238]. Hepatocytes maintained in the monolayer culture had a 
rapid loss of urea function while the spheroid-cultured hepatocytes demonstrated elevated 





Figure 4.3. Cell morphology and hepatocyte specific functions in spheroid-cultured simian 
hepatocytes. (a) Bright field images of cell morphology of simian hepatocytes in spheroid 
culture in 3D Cellusponge and monolayer cultures on days 1, 4, 14 and 60 (20X). (b) 
Live/dead staining of hepatocytes using calcein-AM/PI in spheroids cultured in 3D 
Cellusponge on day 5 and day 30 respectively (c) Hepatocyte specific function of urea 
production in monolayer culture and spheroids on 3D Cellusponge for days 2, 4, 6, 8, 10, 
13 and 22 post cells seeding. *p <0.05 for two-tailed t-test against collagen monolayer 
samples. Data expressed as mean ± SEM.  
(c)
(b) Day 5 Day 30
(a)





































4.3  Characterization of spheroid-cultured human primary hepatocytes 
(collaboration with NUS) 
Unlike the simian hepatocytes spheroid system, which is novel, spheroid-cultured 
human primary hepatocytes have already been extensively studied and shown to generate 
stable and functional hepatocytes to sustain an in vitro viable HCV infection [98]. We next 
evaluated the functionality of the spheroid-cultured human hepatocytes as they are the 
target platform for studying relapses of P. vivax infections. To establish the expression and 
localization of Plasmodium entry marker (CD81) and apical and basolateral markers 
(MRP2 and CD147), immunostaining was carried out after 5 days of culture. The spheroid- 
cultured human hepatocytes were positive for CD81, MRP2 and CD147. The CD81 and 
CD147 were localized at the basolateral domain and MRP2 was localized at apical domain 
(Figure 4.4a and b). The localization of the markers was similar to that observed in the in 
vivo liver). We next evaluated the functionality of the spheroid-cultured human hepatocytes 
by incubating the spheroids in the presence of fluorescein diacetate (FDA) to determine the 
presence functional esterases. The fluorescein produced from FDA by esterases 
accumulated between the hepatocytes on day 5 of culture appeared as punctuated spots 
which demonstrated the presence of functional bile canaliculi and functional hepatocytes 
(Figure 4.4c). The basal transcript and metabolism of the human hepatocytes cultured in 
the 3D Cellusponge and collagen monolayer were evaluated next. The human hepatocytes 
cultured as spheroids in the 3D Cellusponge demonstrated similar mRNA levels of 







Figure 4.4. Cell morphology and hepatocyte specific functions in spheroid-cultured human 
hepatocytes (a) Spheroid-cultured human hepatocytes stained for both MRP2 and CD147, 
which are apical and basolateral markers of polarity. Scale bar at 20 μm (b) The spheroid 
cultured hepatocytes were also stained for CD-81, a basolateral marker and also a 
plasmodium entry marker. Scale bar at 20 μm. (c) The spheroids stained with fluorescein 
di-acetate (FDA) demonstrating punctuated distribution of fluorescein between the 
hepatocytes, thus proving the presence of functional bile canaliculi and apical polarity. 
Scale bar at 20 μm. (d) The human hepatocytes cultured in spheroid cultures demonstrated 
similar transcript levels of CYP1A2 and CYP 3A4 in comparison to monolayer cultures. 
This demonstrated the presence of functional metabolic activity necessary for drug 
metabolism and activity. 
(d)(c)
(b)(a)






































4.4  P. cynomolgi infection of spheroid-cultured simian hepatocytes 
The susceptibility of pre-formed (four days old) spheroid-cultured simian 
hepatocytes in the 3D Cellusponge to P. cynomolgi sporozoites was examined. To 
determine the most suitable sporozoites load for optimal infection in spheroid-cultured 
hepatocytes, three different MoIs (multiplicity of infection) of 0.7 (as per monolayer 
culture), 2 and 4 were assessed on spheroids (Figure 4.5). In this study, MOI refers to the 
ratio of sporozoites to primary hepatocytes infected. Immunostaining using antibody 
specific for P. cynomolgi HSP70 (anti-PcHSP70) were carried out to determine the level 
of infection by P. cynomolgi sporozoites. A MoI of 2 was selected for infection as it gave 
the most efficient rate of infection as it gave comparable level of infection as with a MoI 
of 4. As sporozoites are extracted from the salivary glands of infected mosquitoes, they are 
usually accompanied by microbes and debris from the mosquitoes. Using half the number 
of sporozoites load reduced the risk of contamination associated with large sporozoites 
inoculum. The analysis of exo-erythrocytic stages in the 3D spheroids proved challenging 
due to the distribution of the schizonts and hypnozoites along all 3 axis of the spheroid and 
macroporous scaffold. Coupled with the lack of z-resolution in current confocal 
microscopy techniques, it was difficult to quantify the infection rates in the spheroids 
formed in the scaffold. In this study, to evaluate the infectivity of the infected 3D spheroids, 
the relative fluorescence units (RFU) of the anti-PcHSP70 antibody on the exo-erythrocytic 
forms were determined for respective treatments. Next, the system was validated for 
potential drug screening purposes. Four days post-infection (dpi), the infected spheroids 
were treated with 0.1% (v/v) DMSO (negative control), 200 nM atovaquone and 500 nM 
of primaquine [211]. Atovaquone is known to inhibit liver schizonts but not hypnozoites 
while primaquine is a potent inhibitor of both liver schizonts and hypnozoites [211]. The 
inhibitory concentrations employed were pre-determined using the standard six days liver-
stage assay on monolayer culture as previously described [88, 211].  
To rule out non-specific binding of anti-PcHsp70 antibody and the presence of 
remnant sporozoites attached on the surface of hepatocytes in 3D culture, immunostaining 
of both treated and untreated samples was carried out as alternative antibodies against P. 
cynomolgi exo-erythrocytic forms were limited (Figure 4.6a). Relative fluorescence units 
(RFU) of anti-PcHSP70 antibody were quantified for the respective treatments. A strong 
signal was found in infected samples treated with 0.1% DMSO control (RFU of 0.09) while 
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infected samples that received treatment with atovaquone and primaquine resulted in a 
reduced (RFU of 0.018) or near the limit of detection signal (RFU of 0.003) respectively 
(Figure 4.6b). The results were reproducible in every subsequent experiment (n > 8) and in 
agreement with the report on P. vivax causal prophylactic experiments on human liver-






Figure 4.5. Determination of multiplicity of infections (MoI) for optimal P. cynomolgi 
infection in spheroid cultured simian hepatocytes.  Four days old spheroid cultured simian 
hepatocytes were infected with different MoIs and fixed on day 6 post-infection. Parasites 
were visualized with the confocal microscope (Olympus FV-1000 at 60X magnification 
with oil lens) using the P. cynomolgi specific antibodies PcHsp70. DNA was labelled using 
DAPI. Scale bar at 20 m. 


















Figure 4.6. P. cynomolgi liver-stage parasites in pre-formed, infected spheroid-cultured 
simian hepatocytes. Parasites were visualized by confocal microscopy (60X) using the P. 
cynomolgi specific antibodies PcHsp70. DNA was labelled with DAPI. Scale bar at 20 m. 
(a) P. cynomolgi infection in pre-formed spheroids in 3D Cellusponge 6 days post-
infection. Four days old pre-formed spheroids were infected with P. cynomolgi sporozoites 
(MoI: 2), exposed to 0.1% DMSO control, 200 nM atovaquone or 500 nM primaquine from 
d4 to d6 post-infection. (b) Rate of P. cynomolgi infections in pre-formed, infected 
spheroids. Fluorescence intensity was quantified using Imaris and normalized to DAPI 
fluorescence intensity *p < 0.05 for two-tailed t-test against 0.1% DMSO samples. Data 





































































4.5  P. cynomolgi infection in simian hepatocytes maintained in suspension 
increases yield 
To improve the rate and consistency of infection while decreasing the overall 
duration of the experiment, we set out to infect the primary simian hepatocytes in 
suspension prior to seeding in the 3D Cellusponge. The rationale for infecting the simian 
hepatocytes in suspension originated from previous studies demonstrating increased rate of 
hepatitis B virus (HBV) infection [239] and also enhanced rate of transduction in 
suspension primary hepatocytes [240, 241]. Previous attempts at seeding pre-infected 
hepatocytes onto collagen-coated 96-well plates failed to yield confluent cultures. 
Furthermore, only few scattered infected cells were detected via an immunofluorescence 
assay (IFA) at six days post-infection suggesting that infection in suspension compromised 
the integrity of surface proteins required for cell adhesion and attachment in monolayer. In 
contrast, the seeding of pre-infected hepatocytes onto the 3D Cellusponge proved highly 
permissive and reproducible (Figure 4.7a and 4.7b). The infected spheroids were treated 
with 0.1% DMSO, 200 nM atovaquone and 500 nM of primaquine at four days post-
infection and fixed at ten days post-infection. Relative to 0.1% DMSO controls (RFU of 
0.3), the atovaquone treated samples (RFU of 0.2) showed a reduction in the parasitic load 
in the spheroids while infections in the primaquine treated samples were mostly eradicated 
(RFU of 0.04) based on anti-PcHsp70 immunostaining (Figure 4.7b). Next, the different 
rate of infectivity between the two different methods of infection was assessed. P. 
cynomolgi infection was around 4-fold higher when the simian hepatocytes were infected 
in suspension before seeding and spheroid formation as compared to infection in pre-
formed spheroids for 0.1% DMSO control (Figure 4.7b).  
To demonstrate the presence of viable parasites in the infected hepatocytes within 
the spheroids, infected and uninfected spheroids were dissociated and plated on collagen-
coated 96-well plates. The samples were then immunostained with anti-PcHsp70 and 
antibodies specific to P. cynomolgi Upregulated in Infective Sporozoites 4 protein (anti-
PcUIS4) and visualized for P. cynomolgi liver stages (Figure 4.8a). Apart from co-
localizing within the infected cell the HSP expressing P. cynomolgi parasites, the anti-
PcUIS4 antibody could clearly demarcate the parasitophorous vacuole membrane (PVM) 
circumference of both the liver schizonts and hypnozoites which were represented in the 
top panel of Figure 4.8a. A distinct and well-defined PVM was only seen in the 
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hypnozoites. PVM prominence is a distinct feature of P. vivax, the human equivalent of P. 
cynomolgi; which shares a similar liver-stage life cycle. Accordingly, the PVM is usually 
observed in the initial stages of infection [91]. The dimensions noted for both liver stages 
concurred with those observed by other groups [91, 211]. This clearly demonstrated that 
not only did the infection of suspension hepatocytes increased the infectivity of the 
hepatocytes, the parasites were viable and able to develop within the infected cell.  
 
4.6  3D Cellusponge captures P. cynomolgi pre-erythrocytic merozoites reinvasion 
in vitro  
Once established that the P. cynomolgi sporozoites infect the spheroid-cultured 
hepatocytes in the 3D Cellusponge, the next aim was to determine whether maturing liver 
schizonts and hypnozoites could develop pre-erythrocytic merozoites and proceed to 
invade simian erythrocytes. Simian erythrocytes were used based on previous work, which 
determined that in contrast to P. vivax, P. cynomolgi preferentially infect simian 
erythrocytes followed by simian reticulocytes and to a lesser extent human reticulocytes 
but not human erythrocytes [242] . Successful infections of the spheroids were first 
confirmed by immunostaining with anti-PcHsp70 antibody (data not shown). At seven, ten 
and 14 days post-infected spheroids were overlaid with simian erythrocytes. The overlaid 
blood was sampled and evaluated via Giemsa staining for viable parasites after 48 hours of 
co-incubation with the spheroids. Infected RBCs were recovered from the 48 hours co-
incubated blood overlays harvested on days nine and 16 (Figure 4.8b). Ring and trophozoite 
stage parasites were detected in the infected erythrocytes from samples on days nine and 
16 but not 12. These blood stage parasites detected might result from the burst of pre-
erythrocytic merozoites from the schizonts on day nine and from the reactivated hypnozoite 
in day 16 as it has been previously been reported that schizonts mature and burst within 
day 11 post-infection [211]  Overall these results indicated that the liver-stage parasites 
were viable, able to develop into multiple pre-erythrocytic merozoites and complete the 








Figure 4.7. P. cynomolgi liver-stage parasites in suspension-infected spheroid-cultured 
simian hepatocytes. Parasites were visualized by confocal microscopy (60X) using the P. 
cynomolgi specific antibodies PcHsp70. DNA was labelled with DAPI. Scale bar at 20 m. 
(a) P. cynomolgi liver-stage parasites in suspension-infected spheroids in 3D Cellusponge 
10 days post-infection. The infected spheroids were exposed to DMSO control, 200 nM 
atovaquone or 500 nM primaquine from day 4 to day 10 post-infection. (b) Comparison of 
the rate of P. cynomolgi infections in the two distinct methods of infection for spheroid 
cultured simian hepatocytes. Fluorescence intensity was quantified using Imaris and 
normalized to DAPI fluorescence intensity, *p < 0.05, **p < 0.001, ***p < 0.0001 for two-
tailed t-test between samples infected by the different methods undergoing the same drug 





Figure 4.8. Progression of exo-erythrocytic forms in the suspension-infected spheroid-
cultured simian hepatocytes. (a) P. cynomolgi liver-stage parasites cultured one day in 
monolayer culture, after dissociation of infected spheroids from 3D Cellusponge 10 days 
post-infection (MoI: 2). Scale bar at 20 m. (b) Complete liver-stage cycle of P. cynomolgi 
in vitro. Ring stage and trophozoite stage of P. cynomolgi in erythrocytes from blood 
overlay initiated on day seven and day 14 post infected spheroid-cultured hepatocytes on 
3D Cellusponge.  
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4.7  Malaria-infected spheroids in 3D Cellusponge is a predictive platform for 
anti-relapse drug evaluation for exo-erythrocytic stages 
The spheroid-cultured hepatocyte model allowed us to widen the capabilities for 
long-term culture of infected simian hepatocytes from the established monolayer culture 
for simian liver-stage compound-screening assay [88, 93, 211]. We next questioned 
whether the model could be used to study invasion of RBCs from maturing liver schizonts 
and relapse from hypnozoites (radical cure) in vitro. The same conditions (seeding of pre-
infected hepatocytes) and controls (atovaquone, primaquine and DMSO) were used.  In 
addition, the phosphatidylinositol-4-OH kinase (PI(4)K) inhibitor-KDU691 (2 M) [66] 
was used as an exploratory tool compound to evaluate the potential of the spheroid infection 
model for radical cure determination. KDU691 was chosen because it was previously 
proven to be active in the 2D collagen coated plates but failed in the in vivo radical cure 
model using rhesus monkeys [93, 94]. A high inhibitory concentration of KDU691 (2 M) 
was chosen to demonstrate its maximum inhibitory effect in the system while being non-
cytotoxic to the simian hepatocytes. Three different experimental models were set up 
(Figure 4.9a) using the same batch of simian hepatocytes and P. cynomolgi sporozoites: (i) 
a causal prophylaxis model whereby treatment was initiated at the time of seeding of the 
infected hepatocytes and terminated on day five, (ii) a delayed-treatment model whereby 
the drugs were added on day four and refreshed every second day (days six and eight) 
followed by termination on day ten and (iii) a radical cure model based on the delayed-
treatment model except that drugs were removed by three consecutive washing on day 16 
and the experiment was terminated five days later (day 21).  
The spheroid causal prophylaxis model (Figure 4.9b) mirror in-house and published 
literature on the standard six days monolayer culture based assay [66, 93]. In this model, 
atovaquone had poor inhibitory activity, while primaquine and KDU691 eradicated the 
parasites compared to the untreated DMSO negative control in the delayed-treatment model 
(Figure 4.9c), atovaquone once again displayed poor inhibition while primaquine 
eradicated the parasite. Noteworthy and in contrast to the causal prophylactic model, there 
was an increase in parasites in the KDU691 treated samples. In the radical cure model 
(Figure 4.9d), some parasites reappeared in the primaquine treated samples. The extent of 
parasites observed in the KDU691 treated samples was similar to the staining profile of the 
DMSO negative control. Consistent with the in vivo data, these results confirmed that 
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KDU691 did not inhibit hypnozoites [94]. Once KDU691 was removed on day 16, 
hypnozoites could mature into liver-stage schizonts and merozoites as indicated by the 











Figure 4.9. Models for studying P. cynomolgi liver-stages in vitro. Parasites were 
visualized with the confocal microscope (60X) using the P. cynomolgi specific antibody 
PcHsp70 (b, c, d). DNA was labelled with DAPI. Scale bar at 20 m. (a) Summary of 
models for studying P. cynomolgi liver-stages in vitro. (b) P. cynomolgi infected spheroids 
in 3D Cellusponge used in a causal prophylaxis model. Suspension infected simian 
hepatocyte (MoI: 2) were exposed to DMSO control, 200 nM atovaquone (ATQ), 500 nM 
primaquine (PQ) or 2 M of KDU691 from the day of infection to day 5 post-infection. (c) 
P. cynomolgi infected spheroids in 3D Cellusponge used in a delayed treatment model. 
Infected spheroid-cultured simian hepatocytes (MoI: 2) were exposed to DMSO control, 
200 nM atovaquone, 500 nM primaquine or 2 M of KDU691 from the day 4 to day 10 
post-infection. (d) P. cynomolgi infected spheroids in 3D Cellusponge used in a potential 
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to DMSO control, 200 nM atovaquone, 500 nM primaquine or 2 M of KDU691 from the 
day four to 16 post-infection and fixed on day 21 post-infection. Fluorescence intensity of 
P. cynomolgi infection in the three experimental models under various drug treatments was 
quantified using Imaris and normalized to DAPI fluorescence intensity *p < 0.05, **p < 
0.001 for two-tailed t-test of different drug treatments against 0.1% DMSO samples within 




4.8  P. vivax infection validates the liver-stage model using spheroid-cultured 
hepatocytes 
To demonstrate the relevance of the P. cynomolgi spheroid-cultured simian 
hepatocyte model in drug screening for human P. vivax exo-erythrocytic stages, the model 
was repeated using human primary hepatocytes and P. vivax sporozoites. To secure fresh 
supply of P. vivax sporozoites, the experiment was carried out on-site at the SMRU, 
Thailand. The infection of the monolayer culture was carried out 24 hours post-seeding as 
previously described [93, 211].  The same human primary hepatocytes used in the 
monolayer system were infected in suspension prior to seeding in the 3D Cellusponge at a 
MoI of 2. Like in the P. cynomolgi 3D spheroid model, the P. vivax infected spheroids were 
treated with 0.1% DMSO, 200 nM atovaquone and 500 nM of primaquine at four days 
post-infection and fixed at ten days post-infection. Immunostaining using antibody specific 
for P. vivax UIS4 (anti-PvUIS4) were carried out to determine the level of infection by P. 
vivax sporozoites (Figure 4.10a). Like in the P. cynomolgi 3D model, the level of P. vivax 
infection was highest in the 0.1% DMSO samples followed by the atovaquone and 
primaquine treated samples (Figure 4.10b). Overall, these results verified that the P. 
cynomolgi spheroid-cultured simian hepatocyte model is reproducible using the human P. 




Figure 4.10. Spheroid-cultured human hepatocytes used for P. vivax infection (a) 
Parasites were visualized with the confocal microscope (60X) using anti-PvUIS4 
antibody specific for P. vivax and DAPI for DNA staining. Scale bar at 30 µm (A to 
D) and 100 µm (E to H). Infected human hepatocytes in spheroids (B, C, D) and in 
monolayer culture (F, G, H) were exposed to 0.1% DMSO control, 200 nM 
atovaquone or 500 nM primaquine from day 5 to day 8 post-infection. (b) 
Fluorescence intensity of P. vivax infection in spheroid-cultured human hepatocytes 
under various drug treatments was quantified using Imaris and normalized to DAPI 
fluorescence intensity, *p <0.05 for two-tailed t-test against 0.1% DMSO samples. 
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5.1  Overview 
In 1912, the first protocol for in vitro cultivation of the erythrocytic stages of 
malaria parasite was made for P. falciparum, P. malariae and P. vivax, though growth was 
restricted to a few cycles [243]. Sustained multiplication over extended periods (months), 
i.e. continuous cultures, proved elusive and was only achieved in 1976 for P. falciparum 
[174, 244] after persistent efforts which spanned across three decades. Within a few years, 
the continuous cultivation of four macaque parasites, P. knowlesi, P. cynomolgi, P. inui 
and P. fragile were reported [245]. More recently the continuous culture, and humanization 
of P. knowlesi was subsequently exploited to carry out genetic and biological studies [183, 
246]. 
In the case of P. falciparum and P. knowlesi, the establishment of tractable long 
term in vitro culture has led to significant gains in our understanding of these important 
pathogens. In stark contrast, the continued failure to develop a continuous culture system 
for P.vivax has greatly hampered efforts to develop drugs and vaccines capable of 
eliminating relapsing malaria. The success of 2 other groups in the 1980s to culture 
P.cynomolgi, encouraged us to reexamine and exploit this neglected approach to 
understanding its important sister species P.vivax.  
This study was set out to achieve two main objectives: 
I. Re-establish the continuous culture of P. cynomolgi erythrocytic stages to 
facilitate its use as the physiologically relevant model to understand its human 
counterpart, P. vivax. 
II. Develop an in vitro model using P. cynomolgi exo-erythrocytic stages for better 
evaluation of hypnozoitocidal compounds. 
5.2  Continuous culture of Plasmodium cynomolgi Berok K4 erythrocytic stages  
The original P. cynomolgi Berok strain was originally extracted from a mixed P. 
cynomolgi-P. fieldi infection in a wild M. nemestrina isolated in peninsular Malaysia during 
the early 1960s, and subsequently maintained by blood and/or sporozoite inoculation 
mainly in M. mulatta and later also in Aotus monkeys [165]. Clonal diversity is well known 
to exist even in single isolate of a parasite species [247-249]. It is unknown whether the 
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Berok line derived from monkey K4 that thrived in this study was selected from a 
genetically heterogeneous P. cynomolgi population, or as a phenotypic variant from an 
otherwise clonal population. Deciphering the mechanism for this preferential growth could 
provide fundamental insights on the cultivation of blood stage malaria parasites. It is 
possible that other P. cynomolgi lines, or from other malaria species, would also be 
amenable to continuous blood stage cultivation, provided that the initial failures are met 
with a patient and systematic study of various culture conditions. The heterogeneous Berok 
K4 and homogenous Berok K4-A7 lines from P. cynomolgi, a species proven as an 
excellent surrogate for P. vivax research will be disseminated globally so as to increase the 
scope of investigations using this physiologically relevant surrogate to propel P. vivax 
blood stages research. 
Since the first reports of in vitro culture of P. cynomolgi by Nguyen et al. and Zhou 
et al. in the 1980s, the potential of the system was neither repeated nor further exploited 
probably due to the almost universal focus on the newly developed P. falciparum culture 
method, developed in 1976 [174]. In this study, through meticulous testing of various 
culture conditions we were able to re-establish and improve the continuous culture of P. 
cynomolgi, we were also able to utilise its robust in vitro growth for a range of genotypic 
and phenotypic studies.  
For the growth medium used in our study, apart from combining the supplements 
used by both Nguyen et al. and Zhou et al., we also replaced L-glutamine with GlutaMAX 
due to its enhanced stability [250] (Table 5.1).  One novel and critical finding, is that 
antibiotics are not added to the growth medium (which is a standard practice in P. 
falciparum continuous culture). We repeatedly observed that antibiotics have a negative 
effect on the growth of P. cynomolgi Berok K4 in vitro (Figure 3.4c) which ultimately 
eradicates the culture.  
 Unlike the study by Nguyen et al., we were unsuccessful in growing the parasites 
in human serum (despite ensuring agglutination was not observed with the combination of 
different batches of human serum used with M. fascicularis erythrocytes). Our initial 
success with continuous culture of Berok K4 was possible using suitable donors of M. 
fascicularis serum and erythrocytes despite being non-autologous. However, it is important 
to note only serum collected from certain M. fascicularis donors were able to sustain 
parasite amplification while serum from other donors gave lower rates of amplification 
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despite the fact that serum collected from all donors were processed and stored in a standard 
manner. Such phenomenon was also noted for the naïve M. fascicularis erythrocytes used 
to sustain the cultures. To reduce batch-to-batch variation of serum and also minimize the 
reliance on macaque samples, the M. fascicularis serum was successfully substituted with 
fetal bovine serum for the continuous culture of the homogeneous Berok K4-A7 strain. 
However, it was still necessary to retain the use of suitable M. fascicularis erythrocytes for 
continuous culture.  
Even with growth conditions optimized for P. cynomolgi Berok K4 continuous 
culture, robust growth appears to be limited to certain P. cynomolgi strains. Not only did 
M or B strains failed to grow in vitro in our hands, but it appears that there’s a sub-
population (K4) from the heterogeneous Berok strain which was more adaptable for in vitro 
cultivation.  
  
Table 5.1.  Summary of culture conditions used for in vitro cultivation of P. cynomolgi 
In this study Nguyen et. al. (1981) Zhou et. al. (1984)
P. cynomolgi strain Berok K4 
Berok K4-A7
Berok Vietnamese
Days of in vitro culture > 180 42 > 140
Growth medium RPMI1640 with 
Glutamax, 30 mM 
HEPES, 200	� M 
hypoxanthine, 0.2% 
(w/v) glucose
RPMI1640 with 30mM 
HEPES
RPMI1640 with 0.03% 
(w/v) glutamine, 0.6% 
(w/v) HEPES, 0.2% 
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20% fetal bovine serum










Trophozoite morphology Amoeboid Less amoeboid Amoeboid
Amplification fold change 3 to 15 2 to 3 3 to 8
Culture restart from frozen 
stabilate
Yes n.a. Yes
Amplification fold change 
of thawed stabilate
3 to 8 n.a 3 to 8
Reproducibility Yes (across 6 labs) No No
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Routine cultivation of the continuous culture of P. cynomolgi Berok K4 can be 
easily initiated from cryopreserved stocks using conditions and methodology that were 
optimized in this study to enable robust growth and large-scale production of the parasite 
when necessary. The parasites of the continuous culture of P. cynomolgi Berok K4 are 
indistinguishable from in vivo parasites, and they retain their infectivity to monkeys and to 
mosquitoes to generate infective sporozoites. The cultured P. cynomolgi Berok K4 share 
several of the morphological, phenotypic and rheological characteristics of P. vivax-
infected erythrocytes. The trophozoites and schizonts of Berok K4 formed rosettes with 
uninfected erythrocytes, which were as tightly bound to each other as those of P. vivax.  
The homogeneous isolate (cloned from a single infected cell) P. cynomolgi Berok 
K4-A7, was also amenable to robust in vitro cultivation (even in fetal bovine serum 
substituted complete medium), where majority of the distinct morphological characteristics 
seen in parental Berok K4 were retained. The isolation of a homogeneous isolate of P. 
cynomolgi greatly facilitates techniques such as target deconvolution, deep sequencing and 
genetic manipulation, all which may help in elucidating important questions relevant to 
vivax malaria. Of these questions, one of the most important is to identify the molecular 
basis for chloroquine resistance in P. vivax [40, 251]. Despite the fact chloroquine remains 
a first line drug against vivax malaria in many countries (i.e. India), its mechanism of action 
and resistance in P. vivax is poorly studied and controversial [134, 252, 253]. Once we have 
the whole genome of the homogeneous isolate K4-A7 elucidated, we hope that our 
continuing efforts to induce chloroquine resistance will select for a resistant mutant 
daughter clone which can be then re-sequenced in an effort to identify molecular 
polymorphisms associated with this important resistance phenotype. 
The last decade has witnessed some successes in the search for new antimalarial 
compounds, with 17 new drug candidates developed since 2010 [59, 178]. One of the key 
contributions to these discoveries was the development of a standard in vitro P. falciparum 
asexual blood stage SYBR green I proliferation assay adapted to automated screening 
technologies [234]. Such strategies are not possible for P. vivax due to the inability to grow 
the parasite in vitro, and high throughput screening of compounds in vivo in the surrogate 
macaque model would require an excessively large number of P. cynomolgi-infected 
macaques. We validated the potential of the P. cynomolgi Berok K4 continuous culture for 
high throughput screens to possibly identify lead compounds active against P. vivax. It was 
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interesting to note that some of the compounds from the Malaria Box and the Pathogen 
Box® used for the validation of the assay were inhibitory to one but not the other of the 
parasite species used for the validation (P. cynomolgi and P. falciparum). Hence, it is likely 
that drug susceptibility data from in vitro-based P. cynomolgi screens may provide a 
reliable predictor of activity against P. vivax. This is particularly important for high 
throughput search of compounds active against the P. vivax liver stages, which  currently  
relies on P. berghei and P. yoelii, two parasites of rodents [234] which does not form 
relapsing hypnozoites. This led to the development of in vitro-based P. cynomolgi and P. 
vivax liver stage assays [68, 88, 89, 211] for profiling of schizontocidal drugs. One of the 
major logistical challenges in high-throughput screening of the P. cynomolgi liver stages is 
the availability of infective sporozoites which can only be obtained from mosquitoes fed 
on blood collected from P. cynomolgi-infected macaques. The fact that Berok K4 line 
parasites maintained in vitro for extensive duration retain infectiousness to mosquitoes and 
produce gametocytes while in culture promises its eventual use of such in vitro cultures for 
mosquito infections, hence reducing the use of primates while possibly increasing 
sporozoite production. We are currently optimizing mosquito-feeding protocol with the 
emphasis to promote gametocytogenesis, a process known to be highly sensitive to culture 
conditions, which were only defined for P. falciparum over many years [254] . 
It is important to highlight that the P. cynomolgi model provides the malaria 
research community the possibility to understand fundamental biological, immunological 
and pathological responses as well as therapeutic approaches derived from in vitro 
observations and correlate with in vivo experimentations in the natural host. The ability to 
refine or terminate a candidate compound or vaccine formulation through such in vitro-in 
vivo interpretations, significantly enhances the value of this pre-clinical model. 
It is hoped that with the availability of easily maintained in vitro erythrocytic P. 
cynomolgi Berok K4 and K4-A7 parasites which can now be exploited to conduct critical 
fundamental and translational research to develop drugs and vaccines against P. vivax, a 
widespread species whose control will impact the eradication of malaria.   
 
5.3  3D hepatic spheroid model for radical cure prediction 
 The study of P. vivax and search for anti-relapse drugs is often hampered by the 
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lack of physiological relevant in vitro models that are able to capture the entire liver-stage 
life cycle of the parasite including relapses caused by the hypnozoites. In this study, we 
explore the potentials of the 3D hepatic spheroid model that is amenable to research on the 
biology of the liver stage and for anti-relapse drug screening assay for P. vivax.   
The development and use of the 3D hepatic spheroid model has accelerated in 
recent years, driven primarily by toxicology and metabolism studies [255-257]. Recently, 
spheroids have been used in for modeling infectious diseases [98]. Here, we first adapted 
the 3D Cellusponge system originally developed with human, rat and mouse hepatocytes 
to simian un-infected/infected hepatocytes. In this system, 3D hepatic spheroid model 
proved to be a physiologically relevant in vitro model to study relapses arising from the 
hypnozoites. The seeding of pre-infected hepatocytes proved to be more efficient, 
homogenous and enabled the complete liver-stage cycle of the parasite with RBC invasion 
by nascent merosomes. More importantly, this platform proved to work equally well with 
P. vivax infection in human hepatocytes. 
Robust predictable in vitro models for radical cure remain a challenge. A six-day 
monolayer culture system using the collagen-coated plates has been used extensively for 
IC50 determinations of potential anti-liver stage malaria parasites [45, 47, 66, 93]. To date, 
liver-stage drug screens have failed to determine whether drugs inhibit the onset of 
infection (causal prophylactic) or kill the dormant hypnozoites (radical cure). The standard 
in vitro-2D based P. cynomolgi liver-stage assay [93, 211] can identify liver-stage active 
compounds but not discriminate causal prophylactic drugs from radical cure active 
compounds. This is because treatment is administered within the first three hours of 
infection and not when the infection has developed. The in vivo P. cynomolgi model in 
combination with other surrogate liver-stage systems using the rodent malaria parasites P. 
berghei and P. yoelii have successfully been used to screen for antimalarial active 
compounds [42, 67, 258]. These systems have allowed for the identification of several 
compounds active on the phosphatidylinositol 4-kinase (PI(4)K). The PI(4)K inhibitors 
KAI407, LMV599 and KDU691 showed promising antimalarial activity in the P. 
cynomolgi and P. yoelii in vitro liver-schizonts systems and in the P. berghei in vivo models 
[66, 93, 259]. In the in vivo macaque model, KDU691 and LMV599 were found to be 
potent causal prophylactic compounds when co-administered at the time of infection of the 
macaques, but failed to prevent relapse in monkeys that were first infected with P. 
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cynomolgi sporozoites and subsequently administered the compounds [94]. In accordance, 
using the 3D hepatic spheroid model described here, KDU691 proved to be an efficacious 
compound in the causal prophylactic model but not in the radical cure model. In the latter 
model, KDU691 appeared to have lost its cidal activity against the non-dividing 
hypnozoites.  
The liver-stage platform presented here is amenable for use in both P. cynomolgi 
and P. vivax. This will facilitate the study of the respective parasites’ liver-stage cycle and 
selection of efficacious hypnozoitocidal compounds. Not only can this system be used as 
the penultimate screen for potential radical cure compounds prior to P. cynomolgi 
sporozoites infection in rhesus monkeys, it could also greatly reduce the use of primates 
for compound evaluation and the accompanying cost.  
Much is known today on the biology of the malaria parasites; nevertheless, a 
profound comprehension of the non-dividing phase of the hepatic stage, the hypnozoites, 
remains elusive. The existence of the pre-erythrocytic liver-stage that is associated with 
relapse of P. cynomolgi and P. vivax was first proposed in 1948 [188] and its presence 
shown in humans and non-human primates in the early 1980s [26, 202, 203]. It has taken 
another three decades to witness other breakthroughs on the biology of the malaria liver-
stage, with a few notable exceptions such as the infection of cultured hepatocytes [83, 215, 
260, 261]. A major limitation attributed to the absence of working models has in part been 
overcome by the recent Matrigel monolayer culture [88], the micropatterned co-cultures 
(MPCCs) model [89, 262], human liver-chimeric mice [91] and a high throughput plate 
culture system [68]. Of these, only the micropatterned co-cultures model and the high 
throughput plate culture systems have been shown to be capable to sustain the invasion into 
red blood cells [68, 89, 262]. One advantage of using P. cynomolgi as a surrogate model 
for P. vivax is its ability to invade equally well normocytes and reticulocytes [242]; hence 
facilitating the merosomes invasion into red blood cells. Discrimination between schizonts 
and schizonts originating from hypnozoites could be achieved by treating with KDU691 
during the intermediate phase (days four to ten).  
While the 3D hepatic spheroid model in this study proved to be a suitable model to 
distinguish liver-stage schizontocidal versus hypnozoitocidal compounds and offers an 
interesting system to study the liver-stage biology of the malaria parasites, it is not without 
limitations. The major limitation of the 3D hepatic spheroid model in its present form is 
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quantification of the parasitic load. While analysis of the 3D spheroids by high content 
imaging is possible, it is time-consuming and data intensive. Alternative detection methods 
by RNA-FISH (fluorescent in situ hybridization) or a biochemical assay could be adapted 
for detection. The construction of a transgenic fluorescent reporter P. cynomolgi strain [80] 
could be used as an alternative system for parasite quantification. Here, to evaluate the level 
of P. cynomolgi and P. vivax infection in the cultured spheroids, we quantified the relative 
fluorescent units (RFU) of antibodies specific to either P. cynomolgi HSP70 (anti-
PcHsp70) or P. vivax UIS4 (anti-PvUIS4). To further verify the strong fluorescent signal 
emitted from immunostaining with anti-PcHsp70 was born out of viable hepatic parasites 
in the spheroids and not debris or artefact, the infected spheroids were dissociated and 
plated on 2D collagen coated plates for imaging. DAPI staining in combination with 
immunostaining using anti-PcHsp70 and anti-PcUIS4 clearly demarcated hypnozoites and 
liver schizonts confirming that the signal emitted was primarily from viable parasites. The 
study was further limited in the optimization process for RBC invasion from merosomes 
due to the restricted number of attempts at this experiment which reduced the opportunities 
for trouble-shooting, including media optimization and sampling. Detection of infected 
RBCs would be an ideal alternative assay readout for anti-relapsing drugs. 
The establishment of a 3D hepatic spheroid model provided long-term hepatic 
functions and enhanced permissiveness and development of both P. cynomolgi and P. vivax 
infections. Consequently, the model was also able to capture the full liver stage cycle 
starting with P. cynomolgi sporozoites invasion in the spheroid-cultured hepatocytes and 
the release of the hepatic merozoites resulting in the invasion of simian erythrocytes in 
vitro. It is hoped that this 3D hepatic spheroid model, can be used to evaluate the liver-
stage biology of the parasite and provide a method for discriminating between causal 
prophylactic and cidal antimalarials activity in vitro in both P. cynomolgi and P. vivax 
infections.  
 
5.4 Overall conclusions and future directions 
 P. vivax research has been fraught by the lack of predictive in vitro culture models 
to study the parasite’s life cycle of throughout its erythrocytic and liver stages in the human 
host. In this study, we chose to work with P. cynomolgi since it shares various phenotypic 
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and genetic similarities to P. vivax. Furthermore, in preclinical studies of drug candidates, 
the in vivo P. cynomolgi macaque model has been used as the gold standard for the 
prediction of the pharmacokinetics and the drug’s efficacy in humans. This thesis further 
demonstrates the utility of P. cynomolgi as a model to study P. vivax; by our in vitro 
recreation of its full life cycle using the optimized in vitro culture of its erythrocytic stages, 
and development of a predictive radical cure liver stage model for hypnozoitocidal 
compounds.  
It is hoped that with the continuous culture of P. cynomolgi Berok K4 and K4-A7 
erythrocytic stages, we will be able exploit our in vitro system to minimize the reliance on 
macaques.  Certainly, one of our goals was to replace the source of infected blood from the 
macaques and generate sporozoites using in vitro erythrocytic stages. However, to ensure 
success, additional studies would be needed to determine the rate of infectivity and also the 
percentage of hypnozoites formed by both the heterogeneous K4 strain and the 
homogeneous K4-A7 strains. To evaluate the rate of infectivity, we need to infect more 
macaques with both strains to evaluate patency and relapse patterns so as to expand on our 
initial work (Figure 3.14a). Our preliminary transmission study (Figure 3.14d) suggested 
the Berok K4 strain produced a lower percentage of hypnozoites compared to the M strain, 
such evaluation would have to be repeated with the K4-A7 strain and perhaps the other 
likely clonal strains (K4 –A5, K4-B5 and K4-G5) which were obtained to identify a strain 
which produces a higher rate of hypnozoites.  
One of the most interesting outcomes from this study, is a single cell derived clone 
of P. cynomolgi (K4-A7) which can be readily cultured and manipulated. With the whole 
genome sequence of K4-A7, it is hoped that it can potentially serve as the genetic backbone 
for future work in target deconvolution and genetic manipulation in addressing drug 
resistance, particularly in defining the cause of chloroquine resistance in P. vivax. This is 
especially important since mechanisms of chloroquine resistance appear to be distinct 
between P. falciparum and P. vivax despite gene synteny between the two species [134].  
  While the radical cure liver stage model using P. cynomolgi infected 3D hepatic 
spheroids might allow for the study of the liver stage cycle of the parasite and selection of 
hypnozoitocidal compounds in vitro before preclinical testing in macaque models, some 
limitations exist, particularly for higher throughput screens. To accurately evaluate the 
potency of the liver stage active compounds, it is crucial to develop a quantifiable endpoint 
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measurement of the parasites within the infected 3D hepatic spheroids. Although 
identification of the liver stages of the parasites in the infected 3D hepatic spheroids by 
high content imaging is possible, they are very slow and require large amount of computer 
memory. Alternative detection methods by fluorescently tagged parasites, RNA-FISH 
(fluorescent in situ hybridization) or a biochemical assay could be adapted for a more 
quantifiable detection.  
Apart from direct quantification of liver stage parasites in the infected 3D hepatic 
spheroids, another method of determining the potency of the hypnozoitocidal compounds 
is the measurement of the parasite’s transition from the liver stage life cycle into the 
erythrocytic life cycle through the release of merosomes from the liver stages for invasion 
into naïve host erythrocytes. Though such phenomenon was observed in vitro in this study, 
various conditions can potentially be further optimised to increase the rate of erythrocyte 
invasion which can subsequently be quantitated with FACS. 
The successful establishment of P. cynomolgi in vitro models for both the 
erythrocytic and exo-erythrocytic stages not only enables the malaria community to better 
understand the effects of antimalarials against both the blood and liver stages of P. vivax, 
it can also be used as the model to study other areas of interest in P. vivax such  the 
elucidation of mechanism of drug resistance, the generation of recombinant P. cynomolgi 
parasites to facilitate high throughput drug screening and the mechanism of parasite 




Figure 5.1 P. cynomolgi continuous culture as a surrogate model to investigate antimalarial 
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Appendix A. Plate layout for the isolation of homogenous population of P. cynomolgi Berok K4 






























Total parasites/ well 62500 6250 625 62.5 6.25 0.625 0.0625 0.00625 0.000625 0.0000625 0.00000625 0
iRBC in 1.25%H (µL) 200
uRBC in 1.25%H (µL) 180 180 180 180 180 180 180 180 180 180 180
Transfer over (µL) 20 20 20 20 20 20 20 20 20 20



































Appendix B. FACS readout of clonal dilution plate over time 
 
  
Summary of FACS readouts (normalized to maximum count of uninfected control wells)
1. FACS read on 5 June 2017 20 Days in culture
1 2 3 4 5 6 7 8 9 10 11 12
A 3.38 2.48 0.95 0.10 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00
B 3.39 2.80 0.86 0.11 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
C 1.86 2.61 0.64 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
D 1.89 2.76 0.58 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
E 2.02 2.54 0.73 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
F 2.50 2.53 0.74 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
G 1.93 2.67 0.73 0.07 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
H 1.90 3.36 0.57 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total parasites/ well 62500 6250 625 62.5 6.25 0.625 0.0625 0.00625 0.000625 0.0000625 0.00000625 0
Serial dilution Neat (0.5% P) 10-1 10-2 10-3 10-4 10-5 10-6 10-7 10-8 10-9 10-10 Uninfected RBC
iRBC in 1.25%H (uL) 200
uRBC in 1.25%H (uL) 180 180 180 180 180 180 180 180 180 180 180
Transfer over (uL) 20 20 20 20 20 20 20 20 20 20
2. FACS readout on 30 June 2017 45 Days in culture
1 2 3 4 5 6 7 8 9 10 11 12
A 4.25 2.15 -0.02 2.30 0.01 0.02 0.04 0.02 -0.01
B 4.40 1.10 -0.02 0.01 -0.02 -0.01 0.00 0.02 0.00
C 4.58 -0.01 -0.01 0.00 -0.03 0.01 0.01 0.02 -0.01
D 3.51 -0.02 0.02 0.01 -0.02 0.03 0.01 0.00 0.00
E 4.76 -0.01 -0.01 0.03 -0.01 0.00 0.01 0.00 -0.02
F 3.02 -0.02 -0.01 -0.02 -0.02 -0.01 -0.02 -0.02 -0.02
G 4.61 3.18 0.00 -0.03 -0.02 0.00 -0.02 0.00 -0.01
H 3.50 0.03 0.00 -0.01 -0.01 0.00 0.03 0.01 -0.01
3. FACS readout 9 July 2017 55 days in culture
1 2 3 4 5 6 7 8 9 10 11 12
A 6.41 -0.03 7.89 0.1 0.07 0.05 0.04 -0.02
B 4.24 -0.02 -0.04 -0.02 -0.04 -0.04 0.02 -0.058
C -0.106 -0.071 -0.062 -0.065 -0.03 -0.082 -0.04 -0.05
D -0.106 -0.105 -0.082 -0.081 -0.073 -0.087 -0.089
E -0.064 -0.082 -0.099 -0.068 -0.05 -0.05 -0.082
F -0.103 -0.111 -0.115 -0.07 -0.068 0.24 -0.079
G 7.14 -0.086 -0.075 -0.077 -0.09 -0.086 -0.083
H -0.072 -0.085 -0.09 0.02 -0.05 -0.04 -0.064
4. FACS readout 21 July 2017 68 days in culture
1 2 3 4 5 6 7 8 9 10 11 12
A A5 -0.009 A7 -0.020 -0.033 -0.033 -0.058 -0.003
B B5 -0.063 -0.035 -0.012 -0.014 0.050 -0.030 -0.013
C -0.062 -0.061 -0.062 -0.053 -0.022 -0.014 -0.041 -0.012
D -0.061 -0.063 -0.061 -0.057 -0.044 -0.054 -0.038
E -0.032 -0.046 -0.026 -0.028 -0.001 -0.025 -0.029
F -0.061 -0.059 -0.048 -0.044 0.010 F10 -0.025
G G5 -0.054 -0.067 -0.033 -0.026 -0.034 -0.034
H -0.004 0.050 -0.002 0.090 0.050 0.060 0.020
5. FACS readout 31 July 2017 78 days in culture
1 2 3 4 5 6 7 8 9 10 11 12
A A5 -0.106 A7 -0.083 -0.095 -0.092 -0.082 -0.088
B B5 -0.089 -0.083 -0.081 -0.068 -0.066 -0.077 -0.051
C -0.088 -0.090 -0.085 -0.062 -0.062 -0.085 -0.098 -0.010
D -0.072 -0.094 -0.076 -0.088 -0.055 -0.085 -0.096
E -0.085 -0.061 -0.096 -0.052 -0.053 -0.058 -0.092
F -0.103 -0.085 -0.075 -0.055 -0.054 F10 -0.087
G G5 -0.081 -0.076 -0.065 -0.069 -0.083 -0.082




Appendix C. Table of contribution for collaborative efforts  
Figure 3.8
Phenotypic and rheological characterization of the heterogeneous Berok K4 strain from in vitro 
culture 
A.C.Y.C generated  the P. cynomolgi  Berok K4 sample and was involved in  all the experiments listed, 
inclusive of data analysis.
 Collaborators in NUS conducted the experiments involving specialised equipments (e.g. SEM, AFM, 
AMNIS).
Figure 3.9 Rate of rosetting across different asexual erythrocytic stages of Berok K4 strain
Contributors
A.C.Y.C generated the P. cynomolgi  Berok K4 sample and was involved for the wet mount rosetting 
experiment, inclusive of data analysis together with collaborator from SIgN.
Section 3.6.3 Preliminary results of Oxford Nanopore sequencing of P. cynomolgi  Berok K4-A7 isolate
A.C.Y.C generated the P. cynomolgi Berok K4-A7 DNA used in the whole genome sequencing using both 
Oxford Nanopore and Illumina sequencing. 
Collaborators in SIgN (bioinformaticians) were responsible for assembling and annotating the genome. 
Figure 3.11 Drug susceptibility testing using P.cynomolgi  Berok K4 in vitro  culture
A.C.Y.C generated the P. cynomolgi  Berok K4 sample used for its drug susceptibility testing and the 
subsequent data analysis on both P. falciparum  and P. cynomolgi results. 
Collaborator in NITD was responsible for P. falciparum  drug susceptibility testing.
Figure 3.14 Transmission study from P. cynomolgi  Berok K4 continuous culture
A.C.Y.C generated the P. cynomolgi Berok K4 sample used for the experiment, shared protocols and taught 
the collaborators in BPRC the method for successful continuous culture and analyzed all data generated 
from the transmission study. 
Collaborators in BPRC carried out the transmission study where the yield and infectivity of the sporozoites 
generated from the continuous culture were evaluated. 
Figure 4.4 Cell morphology and hepatocyte specific functions in spheroid-cultured human hepatocytes
Contributors
A.C.Y.C generated the spheroid-cultured human hepatocytes used in the experiment, carried out the 
respective experiments and analysed the data together with the collaborator in NUS.
Contributors
Contributors
Contributors
Contributors
